WO2006117786A1 - Disease therapy using dying or dead cells - Google Patents
Disease therapy using dying or dead cells Download PDFInfo
- Publication number
- WO2006117786A1 WO2006117786A1 PCT/IL2006/000527 IL2006000527W WO2006117786A1 WO 2006117786 A1 WO2006117786 A1 WO 2006117786A1 IL 2006000527 W IL2006000527 W IL 2006000527W WO 2006117786 A1 WO2006117786 A1 WO 2006117786A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- leukocytes
- apoptosis
- monocytes
- dying
- cells
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 176
- 201000010099 disease Diseases 0.000 title claims abstract description 172
- 238000002560 therapeutic procedure Methods 0.000 title description 3
- 210000004027 cell Anatomy 0.000 claims abstract description 254
- 210000000265 leukocyte Anatomy 0.000 claims abstract description 199
- 230000028993 immune response Effects 0.000 claims abstract description 74
- 230000001575 pathological effect Effects 0.000 claims abstract description 61
- 238000002360 preparation method Methods 0.000 claims abstract description 18
- 210000001616 monocyte Anatomy 0.000 claims description 232
- 230000006907 apoptotic process Effects 0.000 claims description 167
- 230000001640 apoptogenic effect Effects 0.000 claims description 121
- 238000011282 treatment Methods 0.000 claims description 112
- 230000001939 inductive effect Effects 0.000 claims description 89
- 230000001225 therapeutic effect Effects 0.000 claims description 81
- 210000004698 lymphocyte Anatomy 0.000 claims description 68
- 230000000770 proinflammatory effect Effects 0.000 claims description 63
- 208000023275 Autoimmune disease Diseases 0.000 claims description 59
- 210000000440 neutrophil Anatomy 0.000 claims description 56
- 230000007246 mechanism Effects 0.000 claims description 51
- 210000002966 serum Anatomy 0.000 claims description 49
- 239000000427 antigen Substances 0.000 claims description 38
- 210000004369 blood Anatomy 0.000 claims description 36
- 239000008280 blood Substances 0.000 claims description 36
- 108091007433 antigens Proteins 0.000 claims description 33
- 102000036639 antigens Human genes 0.000 claims description 33
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 25
- 208000024908 graft versus host disease Diseases 0.000 claims description 25
- 230000037396 body weight Effects 0.000 claims description 21
- 238000002054 transplantation Methods 0.000 claims description 19
- 108090001007 Interleukin-8 Proteins 0.000 claims description 16
- 208000018359 Systemic autoimmune disease Diseases 0.000 claims description 14
- 206010025135 lupus erythematosus Diseases 0.000 claims description 13
- 238000007790 scraping Methods 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 230000001404 mediated effect Effects 0.000 claims description 11
- 230000031972 neutrophil apoptotic process Effects 0.000 claims description 11
- 238000004891 communication Methods 0.000 claims description 10
- 238000000338 in vitro Methods 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 108091005804 Peptidases Proteins 0.000 claims description 8
- 239000004365 Protease Substances 0.000 claims description 8
- 150000003431 steroids Chemical class 0.000 claims description 7
- 108090001005 Interleukin-6 Proteins 0.000 claims description 6
- 210000004988 splenocyte Anatomy 0.000 claims description 5
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 230000001678 irradiating effect Effects 0.000 claims description 4
- 238000005086 pumping Methods 0.000 claims description 4
- 231100000409 cytocidal Toxicity 0.000 claims description 3
- 230000000445 cytocidal effect Effects 0.000 claims description 3
- 230000000861 pro-apoptotic effect Effects 0.000 claims description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 4
- 238000000034 method Methods 0.000 abstract description 124
- 238000002617 apheresis Methods 0.000 description 52
- 239000000725 suspension Substances 0.000 description 49
- 230000028327 secretion Effects 0.000 description 45
- 241000699670 Mus sp. Species 0.000 description 42
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 39
- 102000004127 Cytokines Human genes 0.000 description 38
- 108090000695 Cytokines Proteins 0.000 description 38
- 230000034994 death Effects 0.000 description 28
- 230000004913 activation Effects 0.000 description 27
- 230000001419 dependent effect Effects 0.000 description 27
- 210000001519 tissue Anatomy 0.000 description 26
- 206010028851 Necrosis Diseases 0.000 description 24
- 230000017074 necrotic cell death Effects 0.000 description 24
- 206010061218 Inflammation Diseases 0.000 description 23
- 230000000694 effects Effects 0.000 description 23
- 230000001363 autoimmune Effects 0.000 description 21
- 230000006698 induction Effects 0.000 description 20
- 230000004054 inflammatory process Effects 0.000 description 20
- 241000282414 Homo sapiens Species 0.000 description 19
- 210000004443 dendritic cell Anatomy 0.000 description 19
- 230000002265 prevention Effects 0.000 description 19
- 102000019034 Chemokines Human genes 0.000 description 18
- 108010012236 Chemokines Proteins 0.000 description 18
- 210000001744 T-lymphocyte Anatomy 0.000 description 17
- 210000000987 immune system Anatomy 0.000 description 17
- 230000002757 inflammatory effect Effects 0.000 description 17
- 230000030833 cell death Effects 0.000 description 16
- 238000012258 culturing Methods 0.000 description 16
- 230000005764 inhibitory process Effects 0.000 description 16
- 108020004414 DNA Proteins 0.000 description 15
- 238000002965 ELISA Methods 0.000 description 15
- 102000004890 Interleukin-8 Human genes 0.000 description 15
- 238000013459 approach Methods 0.000 description 15
- 239000002158 endotoxin Substances 0.000 description 15
- 229920006008 lipopolysaccharide Polymers 0.000 description 15
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 15
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 15
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 14
- 102000003777 Interleukin-1 beta Human genes 0.000 description 14
- 108090000193 Interleukin-1 beta Proteins 0.000 description 14
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 14
- 239000000463 material Substances 0.000 description 14
- 210000000056 organ Anatomy 0.000 description 14
- 239000002609 medium Substances 0.000 description 13
- 230000000735 allogeneic effect Effects 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 12
- 230000014509 gene expression Effects 0.000 description 12
- 230000009931 harmful effect Effects 0.000 description 12
- 210000002540 macrophage Anatomy 0.000 description 12
- 239000012528 membrane Substances 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 11
- 230000001464 adherent effect Effects 0.000 description 11
- 230000001338 necrotic effect Effects 0.000 description 11
- 239000000758 substrate Substances 0.000 description 11
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 10
- 102000019145 JUN kinase activity proteins Human genes 0.000 description 10
- 230000003110 anti-inflammatory effect Effects 0.000 description 10
- 230000005784 autoimmunity Effects 0.000 description 10
- 239000012530 fluid Substances 0.000 description 10
- 230000001506 immunosuppresive effect Effects 0.000 description 10
- 238000002955 isolation Methods 0.000 description 10
- 230000035800 maturation Effects 0.000 description 10
- 230000026731 phosphorylation Effects 0.000 description 10
- 238000006366 phosphorylation reaction Methods 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 239000012826 P38 inhibitor Substances 0.000 description 9
- 206010052779 Transplant rejections Diseases 0.000 description 9
- 238000003306 harvesting Methods 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 9
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 8
- 101000577064 Lymnaea stagnalis Molluscan insulin-related peptide 1 Proteins 0.000 description 8
- 101000737895 Mytilus edulis Contraction-inhibiting peptide 1 Proteins 0.000 description 8
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 210000003719 b-lymphocyte Anatomy 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 8
- 238000013518 transcription Methods 0.000 description 8
- 230000035897 transcription Effects 0.000 description 8
- 102100035904 Caspase-1 Human genes 0.000 description 7
- 108090000426 Caspase-1 Proteins 0.000 description 7
- 108010076667 Caspases Proteins 0.000 description 7
- 102000011727 Caspases Human genes 0.000 description 7
- 206010008027 Cerebellar atrophy Diseases 0.000 description 7
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 7
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 208000003455 anaphylaxis Diseases 0.000 description 7
- 210000001185 bone marrow Anatomy 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 7
- 229960004397 cyclophosphamide Drugs 0.000 description 7
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 7
- 239000003018 immunosuppressive agent Substances 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 210000005259 peripheral blood Anatomy 0.000 description 7
- 239000011886 peripheral blood Substances 0.000 description 7
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 6
- 239000005541 ACE inhibitor Substances 0.000 description 6
- 102000053602 DNA Human genes 0.000 description 6
- 206010016207 Familial Mediterranean fever Diseases 0.000 description 6
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 6
- 208000015023 Graves' disease Diseases 0.000 description 6
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 6
- 239000012825 JNK inhibitor Substances 0.000 description 6
- 206010047115 Vasculitis Diseases 0.000 description 6
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 6
- -1 cardiolipin Chemical compound 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 6
- 208000006750 hematuria Diseases 0.000 description 6
- 201000006417 multiple sclerosis Diseases 0.000 description 6
- 206010028417 myasthenia gravis Diseases 0.000 description 6
- 201000001119 neuropathy Diseases 0.000 description 6
- 230000007823 neuropathy Effects 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 210000001539 phagocyte Anatomy 0.000 description 6
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 230000014616 translation Effects 0.000 description 6
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 5
- 108010092776 Autophagy-Related Protein 5 Proteins 0.000 description 5
- 102000016614 Autophagy-Related Protein 5 Human genes 0.000 description 5
- 208000015943 Coeliac disease Diseases 0.000 description 5
- 108010049207 Death Domain Receptors Proteins 0.000 description 5
- 102000009058 Death Domain Receptors Human genes 0.000 description 5
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 5
- 108090000978 Interleukin-4 Proteins 0.000 description 5
- 102000004388 Interleukin-4 Human genes 0.000 description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 5
- 229940118135 JNK inhibitor Drugs 0.000 description 5
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 208000012902 Nervous system disease Diseases 0.000 description 5
- 208000025966 Neurological disease Diseases 0.000 description 5
- 208000007536 Thrombosis Diseases 0.000 description 5
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 5
- 206010003246 arthritis Diseases 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 229940124589 immunosuppressive drug Drugs 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 201000001474 proteinuria Diseases 0.000 description 5
- 208000037803 restenosis Diseases 0.000 description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 5
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 206010043778 thyroiditis Diseases 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 108090000672 Annexin A5 Proteins 0.000 description 4
- 102000004121 Annexin A5 Human genes 0.000 description 4
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 206010062016 Immunosuppression Diseases 0.000 description 4
- 201000002481 Myositis Diseases 0.000 description 4
- 206010028665 Myxoedema Diseases 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 4
- 208000021386 Sjogren Syndrome Diseases 0.000 description 4
- 229920000392 Zymosan Polymers 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 210000000601 blood cell Anatomy 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 238000007887 coronary angioplasty Methods 0.000 description 4
- 239000003246 corticosteroid Substances 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
- 229960003957 dexamethasone Drugs 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 206010014599 encephalitis Diseases 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 230000000762 glandular Effects 0.000 description 4
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 4
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 4
- 230000006058 immune tolerance Effects 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 208000003786 myxedema Diseases 0.000 description 4
- 230000002956 necrotizing effect Effects 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000002103 transcriptional effect Effects 0.000 description 4
- 230000001960 triggered effect Effects 0.000 description 4
- 230000003442 weekly effect Effects 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 3
- 208000023328 Basedow disease Diseases 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 108010092160 Dactinomycin Proteins 0.000 description 3
- 108010039471 Fas Ligand Protein Proteins 0.000 description 3
- 208000018522 Gastrointestinal disease Diseases 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
- 208000003807 Graves Disease Diseases 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 206010020843 Hyperthermia Diseases 0.000 description 3
- 230000004950 I-kappaB phosphorylation Effects 0.000 description 3
- 206010061216 Infarction Diseases 0.000 description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 208000000209 Isaacs syndrome Diseases 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 102000043136 MAP kinase family Human genes 0.000 description 3
- 108091054455 MAP kinase family Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 206010036030 Polyarthritis Diseases 0.000 description 3
- 229940079156 Proteasome inhibitor Drugs 0.000 description 3
- 102000001253 Protein Kinase Human genes 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 206010063837 Reperfusion injury Diseases 0.000 description 3
- 206010039710 Scleroderma Diseases 0.000 description 3
- 108020004682 Single-Stranded DNA Proteins 0.000 description 3
- 206010072148 Stiff-Person syndrome Diseases 0.000 description 3
- 201000009594 Systemic Scleroderma Diseases 0.000 description 3
- 206010042953 Systemic sclerosis Diseases 0.000 description 3
- 102100023132 Transcription factor Jun Human genes 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 3
- 206010002022 amyloidosis Diseases 0.000 description 3
- 230000000469 anti-sperm effect Effects 0.000 description 3
- 230000002785 anti-thrombosis Effects 0.000 description 3
- 230000006472 autoimmune response Effects 0.000 description 3
- 238000010322 bone marrow transplantation Methods 0.000 description 3
- 239000003636 conditioned culture medium Substances 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 229960000640 dactinomycin Drugs 0.000 description 3
- 201000001981 dermatomyositis Diseases 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 230000001667 episodic effect Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000013467 fragmentation Methods 0.000 description 3
- 238000006062 fragmentation reaction Methods 0.000 description 3
- 230000036031 hyperthermia Effects 0.000 description 3
- 230000008629 immune suppression Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000006882 induction of apoptosis Effects 0.000 description 3
- 230000007574 infarction Effects 0.000 description 3
- 208000000509 infertility Diseases 0.000 description 3
- 230000036512 infertility Effects 0.000 description 3
- 231100000535 infertility Toxicity 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 208000028774 intestinal disease Diseases 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 201000008383 nephritis Diseases 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 230000008816 organ damage Effects 0.000 description 3
- 230000002611 ovarian Effects 0.000 description 3
- 229940127255 pan-caspase inhibitor Drugs 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 208000030428 polyarticular arthritis Diseases 0.000 description 3
- 208000005987 polymyositis Diseases 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 239000003207 proteasome inhibitor Substances 0.000 description 3
- 108060006633 protein kinase Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 230000003068 static effect Effects 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000000451 tissue damage Effects 0.000 description 3
- 230000007306 turnover Effects 0.000 description 3
- 230000003827 upregulation Effects 0.000 description 3
- 206010000234 Abortion spontaneous Diseases 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
- 108050008874 Annexin Proteins 0.000 description 2
- 102000000412 Annexin Human genes 0.000 description 2
- 208000008037 Arthrogryposis Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 108091008875 B cell receptors Proteins 0.000 description 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 2
- 101800004538 Bradykinin Proteins 0.000 description 2
- 102400000967 Bradykinin Human genes 0.000 description 2
- 101150013553 CD40 gene Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102000003952 Caspase 3 Human genes 0.000 description 2
- 108090000397 Caspase 3 Proteins 0.000 description 2
- 206010008748 Chorea Diseases 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 101001039702 Escherichia coli (strain K12) Methyl-accepting chemotaxis protein I Proteins 0.000 description 2
- 102100022086 GRB2-related adapter protein 2 Human genes 0.000 description 2
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 2
- 208000022461 Glomerular disease Diseases 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- 206010018378 Glomerulonephritis rapidly progressive Diseases 0.000 description 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 2
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 2
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 2
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 2
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 208000026492 Isaac syndrome Diseases 0.000 description 2
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000021642 Muscular disease Diseases 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- 206010028424 Myasthenic syndrome Diseases 0.000 description 2
- 108010047956 Nucleosomes Proteins 0.000 description 2
- 201000011152 Pemphigus Diseases 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 2
- 206010071141 Rasmussen encephalitis Diseases 0.000 description 2
- 208000004160 Rasmussen subacute encephalitis Diseases 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- 241000272534 Struthio camelus Species 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- 208000001106 Takayasu Arteritis Diseases 0.000 description 2
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 2
- 208000024799 Thyroid disease Diseases 0.000 description 2
- 208000000323 Tourette Syndrome Diseases 0.000 description 2
- 208000016620 Tourette disease Diseases 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 230000002424 anti-apoptotic effect Effects 0.000 description 2
- 208000025150 arthrogryposis multiplex congenita Diseases 0.000 description 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 2
- 201000004339 autoimmune neuropathy Diseases 0.000 description 2
- 208000010928 autoimmune thyroid disease Diseases 0.000 description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
- 229960002170 azathioprine Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 208000002352 blister Diseases 0.000 description 2
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 208000012601 choreatic disease Diseases 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 208000018631 connective tissue disease Diseases 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 201000005637 crescentic glomerulonephritis Diseases 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 238000000432 density-gradient centrifugation Methods 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 208000032625 disorder of ear Diseases 0.000 description 2
- 201000007850 distal arthrogryposis Diseases 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 229960000301 factor viii Drugs 0.000 description 2
- 231100000562 fetal loss Toxicity 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- 210000002816 gill Anatomy 0.000 description 2
- 231100000852 glomerular disease Toxicity 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 229940125721 immunosuppressive agent Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 230000032820 leukocyte apoptotic process Effects 0.000 description 2
- 206010063344 microscopic polyangiitis Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 210000001623 nucleosome Anatomy 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 238000011369 optimal treatment Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000009054 pathological process Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000012342 propidium iodide staining Methods 0.000 description 2
- 201000007094 prostatitis Diseases 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 208000000995 spontaneous abortion Diseases 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 241001316595 Acris Species 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 206010001935 American trypanosomiasis Diseases 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 101710112613 C-C motif chemokine 13 Proteins 0.000 description 1
- 102100023702 C-C motif chemokine 13 Human genes 0.000 description 1
- 102100023700 C-C motif chemokine 16 Human genes 0.000 description 1
- 102100036848 C-C motif chemokine 20 Human genes 0.000 description 1
- 102100031092 C-C motif chemokine 3 Human genes 0.000 description 1
- 101710155856 C-C motif chemokine 3 Proteins 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 102100032366 C-C motif chemokine 7 Human genes 0.000 description 1
- 101710155834 C-C motif chemokine 7 Proteins 0.000 description 1
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 description 1
- 101710098272 C-X-C motif chemokine 11 Proteins 0.000 description 1
- 101710085500 C-X-C motif chemokine 9 Proteins 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 101100026251 Caenorhabditis elegans atf-2 gene Proteins 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 208000024699 Chagas disease Diseases 0.000 description 1
- 108010083700 Chemokine CCL20 Proteins 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 108010078239 Chemokine CX3CL1 Proteins 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010010099 Combined immunodeficiency Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 description 1
- 102100031107 Disintegrin and metalloproteinase domain-containing protein 11 Human genes 0.000 description 1
- 101710121366 Disintegrin and metalloproteinase domain-containing protein 11 Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102100023688 Eotaxin Human genes 0.000 description 1
- 101710139422 Eotaxin Proteins 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 1
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 1
- 108010040476 FITC-annexin A5 Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 102000013818 Fractalkine Human genes 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 1
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 108010058607 HLA-B Antigens Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000027761 Hepatic autoimmune disease Diseases 0.000 description 1
- 208000028523 Hereditary Complement Deficiency disease Diseases 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 101000978375 Homo sapiens C-C motif chemokine 16 Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000950669 Homo sapiens Mitogen-activated protein kinase 9 Proteins 0.000 description 1
- 101000668165 Homo sapiens RNA-binding motif, single-stranded-interacting protein 1 Proteins 0.000 description 1
- 101000684994 Homo sapiens Stromal cell-derived factor 2 Proteins 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102000004125 Interleukin-1alpha Human genes 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 102100035304 Lymphotactin Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000362 Lymphotoxin-beta Proteins 0.000 description 1
- 102100026894 Lymphotoxin-beta Human genes 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101710151803 Mitochondrial intermediate peptidase 2 Proteins 0.000 description 1
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 1
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 1
- 102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 102000018745 NF-KappaB Inhibitor alpha Human genes 0.000 description 1
- 108010052419 NF-KappaB Inhibitor alpha Proteins 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 206010072359 Neuromyotonia Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 102100037602 P2X purinoceptor 7 Human genes 0.000 description 1
- 101710189965 P2X purinoceptor 7 Proteins 0.000 description 1
- 208000016222 Pancreatic disease Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 208000027086 Pemphigus foliaceus Diseases 0.000 description 1
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 102100030304 Platelet factor 4 Human genes 0.000 description 1
- 108090000778 Platelet factor 4 Proteins 0.000 description 1
- 208000025237 Polyendocrinopathy Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000034943 Primary Sjögren syndrome Diseases 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108010016131 Proto-Oncogene Proteins c-jun Proteins 0.000 description 1
- 102000000427 Proto-Oncogene Proteins c-jun Human genes 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 102000004389 Ribonucleoproteins Human genes 0.000 description 1
- 108010081734 Ribonucleoproteins Proteins 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 201000002661 Spondylitis Diseases 0.000 description 1
- 102100023184 Stromal cell-derived factor 2 Human genes 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- 102000056172 Transforming growth factor beta-3 Human genes 0.000 description 1
- 108090000097 Transforming growth factor beta-3 Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 208000024340 acute graft versus host disease Diseases 0.000 description 1
- 230000010398 acute inflammatory response Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000007503 antigenic stimulation Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000005735 apoptotic response Effects 0.000 description 1
- 230000005756 apoptotic signaling Effects 0.000 description 1
- 101150010487 are gene Proteins 0.000 description 1
- 238000009246 art therapy Methods 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 208000026764 autoimmune bullous skin disease Diseases 0.000 description 1
- 208000037896 autoimmune cutaneous disease Diseases 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 102000015005 beta-adrenergic receptor activity proteins Human genes 0.000 description 1
- 108040006818 beta-adrenergic receptor activity proteins Proteins 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 208000000594 bullous pemphigoid Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 238000010822 cell death assay Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 208000017760 chronic graft versus host disease Diseases 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003413 degradative effect Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000012137 double-staining Methods 0.000 description 1
- 210000003027 ear inner Anatomy 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 230000002616 endonucleolytic effect Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000001280 germinal center Anatomy 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000002727 hyperosmolar Effects 0.000 description 1
- 208000009326 ileitis Diseases 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 230000006028 immune-suppresssive effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 108010027775 interleukin-1beta-converting enzyme inhibitor Proteins 0.000 description 1
- 201000006334 interstitial nephritis Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000020121 low-fat milk Nutrition 0.000 description 1
- 230000005427 lymphocyte apoptotic process Effects 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 108010019677 lymphotactin Proteins 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000008965 mitochondrial swelling Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 230000001538 myasthenic effect Effects 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000000715 neuromuscular junction Anatomy 0.000 description 1
- 230000004987 nonapoptotic effect Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 208000015124 ovarian disease Diseases 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000012335 pathological evaluation Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229930192851 perforin Natural products 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 230000007112 pro inflammatory response Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000008741 proinflammatory signaling process Effects 0.000 description 1
- 238000012514 protein characterization Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 208000017443 reproductive system disease Diseases 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000004739 secretory vesicle Anatomy 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 208000021510 thyroid gland disease Diseases 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000025366 tissue development Effects 0.000 description 1
- 230000024664 tolerance induction Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000005758 transcription activity Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000014723 transformation of host cell by virus Effects 0.000 description 1
- 230000009495 transient activation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000013042 tunel staining Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003462 zymogenic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4614—Monocytes; Macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46434—Antigens related to induction of tolerance to non-self
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0023—Agression treatment or altering
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
- A61M1/3486—Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3681—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation
- A61M1/3683—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation using photoactive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3681—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
Definitions
- the present invention relates to methods of using dying cells for treating diseases characterized by pathological immune responses, and to devices for preparing such dying cells. More particularly, the present invention relates to methods of using apoptotic leukocytes, which do not secret pro-inflammatory mediators, for treating diseases characterized by pathological immune responses, such as autoimmune diseases and transplantation-related diseases, and to devices for preparing such apoptotic leukocytes.
- Diseases characterized by pathological immune responses include a large number of diseases which are associated with significant mortality and morbidity, and for which no satisfactory/optimal treatments are available.
- diseases particularly include autoimmune diseases, such as systemic lupus erythematosus (SLE), transplantation-related diseases such as graft- versus-host disease (GVHD).
- SLE systemic lupus erythematosus
- GVHD transplantation-related diseases
- GVHD graft- versus-host disease
- the immune system is a complex network comprising cells, antibodies, tissues, and chemical messenger molecules which allow for communication between these structures.
- a hallmark of a healthy immune system is the ability to recognize bacteria, viruses, and other foreign bodies and to effectively attack such pathogens while continuing to distinguish between the foreign bodies and the molecules, cells, tissues and organs of the body.
- the immune system has other roles in maintaining the normal state of health and function of the body. Throughout the life span of an organism, tissues become reshaped with areas of cells being removed. This is accomplished by a process termed programmed cell death or apoptosis, the apoptotic cells disintegrating in an orderly and harmless fashion and being phagocytosed.
- apoptosis In many organs, for example, a certain percentage of the cells die off every day while different branches of the immune system are typically called in to remove the dead cells and parts thereof to make room for the new cells which arise to replace them.
- the process of apoptosis is furthermore considered to be particularly important in the development and maintenance of the immune system itself, where the immune cells which recognize or attack normal cells of the body are destroyed and removed by this process.
- the number of monocytes, neutrophils, and lymphocytes that are produced, circulating, dying, and extravasating in the body is controlled at various levels, including via apoptosis.
- monocytes CFU-GM
- CFU-GM the earliest identified cell committed to differentiate along the myeloid pathway, develops into monocyte in the bone marrow, mainly in the presence of M-CSF, IL-3, and low levels of GM-CSF.
- Monocytes comprise 1-6 percent of peripheral leukocytes, and it is estimated that 5.7 x 10 6 monocytes/kg are produced every day.
- Monocytes can survive in tissues as macrophages for long periods, but a substantial portion of monocytes are constantly undergoing apoptosis, either in the absence of anti-apoptotic factors or following infection or activation. Monocytes express Fas and Fas ligand irrespective of their state of activation
- Monocytes can be rescued from apoptosis upon exposure to growth factors, differentiating factors (GM-CSF and IL-4), or activation factors [3, 6-8].
- monocytes Upon differentiation to macrophages, monocytes are rescued from Fas-dependent apoptosis by the expression of Fas-associated death domain-like IL-I- beta-converting enzyme-inhibitory protein (FLIP) [3, 9].
- FLIP Fas-associated death domain-like IL-I- beta-converting enzyme-inhibitory protein
- Neutrophils constitute the most abundant population of leukocytes. In humans, the daily turnover of neutrophils is about 1.6 x 10 cells/kg body weight (Klebanoff SJ, Clark RX: The Neutrophil: Function and Clinical Disorders. Amsterdam, North-Holland Publishing, 1978, p 313), which keeps the number of mature neutrophils within defined limits despite the tremendous proliferative potential of the bone marrow precursor cells. This large turnover is mediated by the continuous egress of neutrophils from the circulation. Neutrophils do not return to the circulation but are eliminated by secretion in mucosa or die in the tissues within 1-2 days (Klebanoff SJ, Clark RX: The Neutrophil: Function and Clinical Disorders.
- apoptosis is a process used by the immune system in protecting the body, it is also used to maintain tolerance to self-antigens and therefore allowing the immune system to fulfill its role in distinguishing the body's own cells from foreign bodies.
- Immature dendritic cells have the capacity to engulf apoptotic cells and to acquire and immunologically present their antigens. Immature dendritic cells that capture apoptotic macrophages exposed to killed influenza-virus, mature and activate lymphocytes to mount virus-specific CTL responses in the presence of conditioned media. However, in the absence of infection and conditioned media, immature dendritic cells do not mature following uptake of apoptotic cells and as a consequence are less able to efficiently present acquired antigens.
- immature dendritic cells may have a role in maintaining peripheral tolerance to self-antigens that are permanently created at different sites.
- autoimmunity or SLE-like disease has been observed in mice and humans deficient in receptors important for uptake of apoptotic cells such as ABCl cassette transporter, Mer, and complement deficiencies, as further described hereinbelow. Clearance via specific receptors may dictate specific immune response or tolerance as demonstrated by TGF-beta and IL-IO secretion by macrophages following uptake of apoptotic cells by macrophages.
- cytokines, chemokines, eicosanoids, and additional mediators present in the milieu of the interaction may polarize the immune response.
- autoimmune disease When the immune system is deficient in recognition between self- and non- self-antigens, the result is a state of disease, this may result in the immune system attacking one or more specific self molecules or cells leading to tissue and organ damage, resulting in autoimmune disease. Immunopathology of non-targeted tissues also may be indirectly caused non-specif ⁇ cally as a consequence of inflammation resulting from immune rejection of neighboring cells and tissues. Other than classical autoimmune diseases such as those mentioned hereinabove, it is becoming increasingly apparent that many vascular disorders, including atherosclerotic forms of such disorders, have an autoimmune component, and a number of patients with vascular disease have circulating autoantibodies.
- Autoimmune diseases may be divided into two general types, namely systemic autoimmune diseases, such as SLE and scleroderma, and organ specific autoimmune diseases, such as multiple sclerosis, and diabetes. Many clinically different types and subtypes of autoimmune disease occur. Although each type of autoimmune disease is associated with a spectrum of clinical symptoms and aberrant laboratory parameters, signs and symptoms of autoimmune diseases frequently overlap so that one or more are diagnosed in the same patient. The vast majority cases in which one or more autoimmune disease has been diagnosed are characterized by the presence in the affected subject of antibodies directed against self-antigens, termed autoantibodies.
- Such autoantibodies are often present in tissues at ten to one hundred times the normal level in healthy individuals and give rise to a significant proportion of the organ and tissue damage associated with the particular autoimmune disease.
- myasthenia gravis autoantibodies against a receptor in neuromuscular junction are associated with muscle weakness
- SLE anti-dsDNA antibodies are associated with nephritis in human patients and can cause nephritis upon injection to normal mice.
- the tissue and organ damage is attributed to the presence of autoantibodies and to the inflammation, which arises due inflammatory immune responses set off by autoantibodies.
- Systemic lupus erythematosus is a model disease for understanding and developing inventive treatments for autoimmune disease in general. While it has long been appreciated that DNA and histones are major autoantigens SLE, only recently has evidence been provided that the DNA-histone complex, i.e., nucleosomes, are the preferred targets of autoantibodies in SLE. During apoptosis, the membrane of cells undergoing apoptosis form cytoplasmic blebs, some of which are shed as apoptotic bodies.
- phosphatidylserine an acidic phospholipid that normally resides on the inside of the cell, but flips to the outside of the cell membrane when the cell undergoes apoptosis.
- Phosphatidylserine like cardiolipin, is a major autoantigen for anti-phospholipid antibodies in SLE.
- the irnmunopathology of SLE appears to further involve defective uptake of apoptotic material by macrophages, as observed in the reduced uptake/clearance of apoptotic cells by macrophages from SLE patients in- vitro, and by the high incidence of SLE in patients deficient in the CIq and C4 components of the complement system, which is involved in uptake of targeted antigens.
- Lymphocytes i.e. T-cells and B-cells
- T-cells and B-cells are relatively resistant to apoptosis.
- B-cells and T-cells proliferate and some will differentiate into effector cells.
- Plasma cells secrete antibodies that immobilize pathogens and promote their complement-mediated destruction and Fc (Ig constant region)-receptor- mediated ingestion by certain myeloid cells.
- Fc Ig constant region
- Activated T-cells produce cytokines, some of which promote proliferation and functional activation of B-cells and T-cells themselves, whereas others provide feedback signals to cells of the innate immune system.
- Immune effector mechanisms are highly potent weapons designed for the killing of free pathogens and also pathogen-infected host cells.
- This armory has the potential to destroy healthy cells and tissues because many of the effector molecules, such as pro-inflammatory cytokines, act in a non-antigen-specific manner and also because certain pathogen-specific receptors, such as B-cell receptors (BCRs) and T- cell receptors (TCRs) may cross-react with host antigens.
- BCRs B-cell receptors
- TCRs T- cell receptors
- Immune responses to pathogens therefore pose a potential danger to the host and irnmunopathology occurs with many types of infection.
- chronically activated lymphocytes that are rapidly proliferating, particularly B-cells in germinal centers undergoing Ig-variable gene hyper-mutation, are at risk of sustaining mutations in proto-oncogenes or tumor suppressor genes that could lead to the development of lymphoma and/or leukaemia.
- Multiple regulatory mechanisms have evolved to prevent irnmunopathology. These include functional inactivation of cells of the immune system, a process that is potentially reversible and therefore does not eliminate the danger, and killing of no-longer needed and/or potentially dangerous cells by apoptosis [Marsden and A. Strasser, 2003. Annu. Rev. Immunol. 21:71- 105].
- autoimmune diseases such as SLE
- transplantation-related diseases such as GVHD
- immunosuppressive drugs such as corticosteroids, azathioprine, cyclophosphamide, and cyclosporine. While such drug-induced immunosuppression has resulted, for example, in improvement of the 5 -year survival rate of SLE patients in the last three decades, it is far from being an ideal treatment since no cure is achieved, since such treatment is associated with very serious side- effects, including general immune suppression, leading to high rates of morbidity, and is the primary cause of premature mortality.
- apoptotic donor cells such as apoptotic donor leukocytes
- apoptotic donor leukocytes to facilitate engraftment of donor hematopoietic grafts transplanted into an allogeneic recipient
- extracorporeal photopheresis involves administering to a patient a photoactivatable pigment which can be specifically taken up by specific hematopoietic cells, such as T-cells, and following such uptake harvesting blood, isolating the specific hematopoietic cells, triggering their apoptosis via UV irradiation, and infusing them back into the patient (United States Patent 6,219,584; Crovetti G, et al., 2000, Int. J. Artif. Organs. 23(l):55-62; THERAKOS, Inc. PA, USA).
- This approach has been advocated for treatment of hypersensitivity, graft rejection, or SLE (United States Patent 4,838,852); or for amelioration of GVHD
- the present invention discloses the use of dying or dead leukocytes which are substantially free of pro-inflammatory mediators such as IL-I ⁇ . IL-8 and MIP l ⁇ , for treatment of diseases associated with pathological immune responses, and discloses devices for generating such dying or dead leukocytes.
- This use can be effected in a variety of ways, and these devices can be configured in a variety of ways, as further described and exemplified hereinbelow.
- a cell preparation which comprises dying or dead leukocytes for the manufacture of a medicament identified for the treatment of a disease characterized by a pathological immune response, the dying or dead leukocytes are obtained by inducing live leukocytes to adhere to a surface and are being capable of suppressing the pathological immune response.
- a use of a cell preparation which comprises dying or dead leukocytes for the manufacture of a medicament identified for the treatment of a disease characterized by a pathological immune response, the dying or dead leukocytes do not secrete a pro-inflammatory mediator selected from the group consisting of IL-I ⁇ , IL-8 MIP- l ⁇ MIP- l ⁇ , IL-6 and IL- l ⁇ , and are capable of suppressing said pathological immune response.
- a method of treating a disease characterized by a pathological immune response in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a cell preparation which comprises dying or dead leukocytes, the dying or dead leukocytes being capable of suppressing the pathological immune response, thereby treating the disease in the subject.
- the method further comprises subjecting live leukocytes to a cytocidal treatment selected from the group consisting of in-vitro serum deprivation, treatment with a steroid or steroid derivative, irradiation, and a pro-apoptotic treatment, thereby generating the dying or dead leukocytes.
- a cytocidal treatment selected from the group consisting of in-vitro serum deprivation, treatment with a steroid or steroid derivative, irradiation, and a pro-apoptotic treatment, thereby generating the dying or dead leukocytes.
- the method of treating the disease further comprises inducing live leukocytes to adhere to a surface, thereby generating the dying or dead leukocytes.
- the pathological immune response is directed against at least one antigen
- the dying or dead leukocytes comprise the at least one antigen.
- the dying or dead leukocytes are derived from the subject.
- the dying or dead leukocytes comprise dying or dead splenocytes and/or dying or dead thymocytes.
- the dying or dead leukocytes comprise dying or dead lymphocytes.
- the dying or dead leukocytes comprise dying or dead monocytes.
- the dying or dead leukocytes comprise dying or dead neutrophils.
- the dying or dead leukocytes comprise apoptotic leukocytes.
- the disease is a systemic autoimmune disease.
- the disease is an antibody-mediated autoimmune disease.
- the disease is lupus erythematosus.
- the disease is a transplantation-related disease.
- the disease is graft-versus-host disease.
- administering the cell preparation comprises administering to the subject a total number of the dying or dead leukocytes selected from a range of about 20 million to about 2 billion cells per kilogram body weight of the subject.
- administering the cell preparation comprises administering to the subject at least one unit dose of the dying or dead leukocytes, wherein the unit dose comprises a number of the dying or dead leukocytes selected from a range of about 4 million to about 2 billion cells per kilogram body weight of the subject.
- the dying or dead leukocytes are obtained by subjecting live leukocytes to a cytocidal treatment selected from the group consisting of in-vitro serum deprivation, treatment with a steroid or steroid derivative, irradiation, and a pro-apoptotic treatment, thereby generating said dying or dead leukocytes.
- the medicament comprises a therapeutic effective amount of the dying or dead leukocytes cells which is selected from a range of about 20 million to about 2 billion per kilogram body weight of a subject.
- the medicament comprises a therapeutic effective amount of the cell preparation which comprises a number of the dying or dead leukocytes selected from a range of about 4 million to about 2 billion cells per kilogram body weight of a subject.
- a device for treating a disease characterized by a pathological immune response comprising: (a) a pump for pumping blood from a subject into the device and returning blood to the subject from the device; (b) a leukocytes separator in communication with the pump for separating circulating leukocytes from whole blood; and (c) an apoptosis-inducing chamber or chambers in communication with the leukocytes separator for inducing apoptosis of the leukocytes to thereby obtain apoptotic leukocytes, and further in communication with the pump for administering the apoptotic leukocytes to the subject.
- the apoptosis-inducing chambers comprise a first chamber for inducing apoptosis of monocytes, a second chamber for inducing apoptosis of neutrophils, and a third chamber for inducing apoptosis of lymphocytes.
- a device for inducing apoptosis of leukocytes comprising an apoptosis-inducing chamber or chambers for inducing apoptosis of leukocytes to thereby obtain apoptotic leukocytes, wherein the apoptosis-inducing chamber or chambers is selected from the group consisting of a first chamber for inducing apoptosis of monocytes, a second chamber for inducing apoptosis of neutrophils, and a third chamber for inducing apoptosis of lymphocytes.
- the first chamber comprises a surface for enhancing adherence of monocytes thereto.
- the device further comprises a first reservoir for containing a monocyte medium, wherein the monocyte medium is for inducing apoptosis of monocytes.
- the device further comprises a second reservoir for containing a neutrophil medium, wherein the neutrophil medium is for inducing apoptosis of neutrophils.
- the device further comprises a third reservoir for containing a lymphocyte medium, wherein the lymphocyte medium is for inducing apoptosis of lymphocytes.
- the device further comprises a mechanism for resuspending surface-adherent monocytes.
- the mechanism for resuspending the surface-adherent monocytes is selected from the group consisting of: a reservoir for containing a protease and a mechanism for introducing the protease into the first chamber; a flow-generating mechanism for generating in the first chamber a flow of sufficient force and direction for resuspending the surface-adherent monocytes; and a scraping mechanism for scraping the surface-adherent monocytes off the surface of the first chamber.
- the apoptosis-inducing chamber or chambers comprises an apoptosis-inducing mechanism selected from the group consisting of: an irradiating mechanism for inducing apoptosis; a mechanical mechanism for inducing apoptosis; and a chemical or biochemical substance or environment for inducing apoptosis.
- the present invention successfully addresses the shortcomings of the presently known configurations by providing a method of treating with improved safety and effectiveness diseases associated with pathological immune responses, such as autoimmune diseases and GVHD, by administration of dying or dead leukocytes, by providing a device for generating such leukocytes, and by providing a device for practicing such methods.
- FIG. 1 is a histogram depicting reduction of serum anti-single-stranded DNA antibodies in MRL/MpJ-Fas lpr mice following treatment with syngeneic apoptotic cells. Filled circles, control group of 6 week-old MRL/lpr/lpr mice immunized with vehicle only; open circles, experimental group of 6 week-old MRL/lpr/lpr mice immunized with syngeneic apoptotic cells; filled triangles, control group after 10 weeks of treatment; open triangles, experimental group after 10 weeks of treatment.
- FIG. 2 is a histogram depicting reduction of serum anti-double-stranded DNA antibodies in MRL/MpJ-Fas lpr mice following treatment with syngeneic apoptotic cells. Filled circles, control group of 6 week-old MRL/lpr/lpr mice immunized with vehicle only; open circles, experimental group of 6 week-old MRL/lpr/lpr mice immunized with syngeneic apoptotic cells; filled triangles, control group after 10 weeks of treatment; open triangles, experimental group after 10 weeks of treatment.
- FIG. 3. is a set of fluorescence activated cell sorting (FACS) dot plots depicting induction of monocyte apoptosis by serum withdrawal and substrate- adherence. More than 70 percent of monocytes were annexin V-positive Pi-negative by 12 hours indicating early apoptosis. Secondary necrotic cells represented less than 5 percent of the cells as indicated by annexin V-positive, propidium iodide (PI)- positive cells. The specificity of the apoptotic process was further shown by marked inhibition in the presence of 20 mM zVAD-fmk. The percentage of early apoptotic and secondary necrotic cells is indicated within each histogram. Data is representative of six different experiments.
- FACS fluorescence activated cell sorting
- FIGs. 5a-c depict de-novo transcription of pro-inflammatory cytokine/chemokine mRNAs by monocytes subjected to suspension + serum deprivation.
- Figures 5a-b are gene expression array analyses depicting de-novo transcription of pro-inflammatory cytokine/chemokine mRNAs by monocytes subjected to suspension + serum deprivation at 0 time and 30 minutes, respectively.
- Coordinates (A2, B2), which represent IL-I -beta and coordinates (E3, F3), representing IL-8, show no visible fluorescence at time zero and a marked fluorescence at 30 minutes following apoptosis induction.
- cDNA of IL-6 C3-D3
- IL-1-alpha El-Fl
- Other cDNAs that are present with viable cells and did not change much upon death induction are TGF-beta-1 (A7-B7), IL-2 (C2-D2), and TNF-alpha (A8-B8).
- MIF E6-F6 shows downregulation.
- Coordinates that represent negative controls are (G1-G2, PUC18); and as positive controls (G3-G4, beta-actin) and (G5-G6, G7-G8, E8-F8, GAPDH).
- Chemokine membrane screening showed only IL-8, MIP-I -alpha and MIP-I -beta upregulation (not shown).
- Membranes contained eotaxin, fractalkine, GROa/MGSA, HCC-4, MCP-3, SDF2, PF-4, MDC, HCC-I, I- 309, I-TAC, lymphotactin, MCP-I, MCP-4, MIG, MIP-2, MIP-3-alpha, PlO, SDF-I, RANTES.
- Figure 5c is a data plot depicting representative cytokine and chemokine cDNA level (in arbitrary units) changes as a function of time following induction of cell death. Note that only IL-I -beta, IL-8, and MIP-I -alpha are produced de-novo.
- FIG. 6a is a data plot depicting that the pro-inflammatory cytokine IL-I -beta is produced by monocytes subjected to suspension + serum withdrawal.
- Control PBMCs that contain 20 % monocytes
- IL-I -beta secretion following suspension + serum withdrawal open triangles
- Magnetically isolated monocyes closed triangles
- IL-1-beta or any pro-inflammatory cytokines
- B- and T-lymphocytes closed circles
- polymorphonuclear cells open circles
- IL-1-beta secretion is specific to monocytes that were not allowed to adhere (i.e., monocytes that were subjected to suspension and serum withdrawal).
- FIG. 6b is an ELISA data histogram depicting that pro-inflammatory cytokine/chemokine mRNA and protein are transcribed and translated de-novo by monocytes subjected to suspension + serum withdrawal.
- Inhibition of transcription activity with actinomycin D and translational activity with cycloheximide shows marked inhibition in IL-1-beta cytokine secretion as measured by ELISA in picogram/ml (pg/ml).
- Monocytes that were allowed to adhere during serum withdrawal did not show any production of pro-inflammatory cytokines (not shown).
- monocytes that were allowed to adhere and were triggered to die by other methods of induction of apoptosis such as staurosporine, cyclophosphamide, Fas ligand, and more, always kept their non-inflammatory mode of death (not shown).
- FIG. 7a is an ELISA data plot depicting the secretion of IL-1-beta by monocytes that were subjected to suspension-induced death (and serum withdrawal) but not from viable monocytes, monocytes subjected to hyperthermia-induced necrosis, or apoptotic monocytes that were induced to apoptosis by adherence and serum withdrawal.
- Levels of IL-1-beta (shown in pg/ml) were measured by ELISA at 0, 1, 4, and 24 hours following incubation of viable monocytes (closed circles), monocytes rendered necrotic via hyperthermia (open circles), or monocytes subjected to suspension-induced death (closed triangles). The results indicate that the pro- inflammatory characteristics of suspension-induced monocyetes are not seen in heat- induced necrosis (accidental cell death) and are innate property of monocytes that were not allowed to adhere.
- FIG. 7b is an ELISA data plot depicting IL- I ⁇ secretion (shown in pg/ml) from monocytes which were subjected to suspension-serum withdrawal - induced death and demonstrating that monocyte death via suspension (non adherence) is neither caspase 3- nor caspase 1 -dependent.
- Secretion of IL-I -beta by monocytes subjected to suspension-induced death was neither inhibited with the caspase 1 inhibitor, Z-WEHD (20 micromolar, closed circles), nor with the pan-caspase inhibitor ZVAD-fmk (20 micromolar, open circles).
- FIGs. 8a-c depict that pro-inflammatory cytokine secretion during monocyte apoptosis is not NFkappaB-dependent.
- Figure 8a is a photograph of a Western immunoblotting assay depicting that pro-inflammatory cytokine secretion during monocyte apoptosis is not NFkappaB-dependent. Shown is 37 kDa IkappaB and phosphorylated IkappaB (black arrow).
- Viable monocytes were incubated for 2 hours in the presence of 1 mg/ml zymosan (which triggers TOLL receptors 2 on macrophagesor dendritic cells to mature and produce inflammation) with (lane a) or without (lane b) MGl 32 (a proteasome inhibitor).
- Lanes c and d are monocytes undergoing apoptosis [by the serum withdrawal and adherence avoidance (or suspension) method] at 2 hours (lane c) and 10 minutes (lane d) following zymosan.
- FIG. 8b is a bar-graph depicting that IL-1-beta secretion in the presence of MG132 is slightly elevated (3 experiments).
- Figure 8c is a histogram depicting transcriptional activity in the presence of MG132 (representative of 3 experiments). Note that fold increases in the levels of mRNA (filled bars) are not changed in the presence of MGl 32 (empty bars).
- FIGs. 9a-e depict that pro-inflammatory cytokine secretion during monocyte apoptosis is p38 -dependent.
- Figure 9a is a bar-graph depicting that after 24 hours in the presence of anti-Fas inhibitory antibodies (BD29 or ZB4), monocyte apoptosis was only slightly decreased (BD29 is shown) compared to the significant * (p ⁇
- Figure 9b is a Western immunoblotting assay depicting that P38 is expressed at comparable levels in monocytes exposed to LPS or induced to undergo apoptosis.
- Figure 9c is a Western immunoblotting assay depicting that phosphorylated p38 is transiently increased upon LPS stimulation but shows sustained increase upon apoptosis. No phosphorylation of JNK was found (not shown). Results are representative of six experiments.
- Figure 9d is a bar-graph depicting that IL-I-
- FIG. 10 is a schematic diagram depicting a device for inducing apoptosis of leukocytes. Arrows indicate direction of fluid flow.
- FIG. 11 is a schematic diagram depicting a device for treating a disease characterized by a pathological immune response. Arrows indicate direction of fluid flow.
- FIGs. 12a-d are FACS analyses depicting that apoptotic monocytes engulfment down-regulates the expression of maturation-related molecules on dendritic cells (DCs).
- DCs dendritic cells
- Adhered apoptotic monocytes (which were generated by adherence and serum withdrawal were stained with DiI (a lypophilic dye that stains dying cells) and were added to immature dendritic cells (iDCs), at a 4:1 ratio.
- the iDCs acquired apoptotic cell-derived DiI and were exposed (bolded line) or not (black line) to LPS.
- the present invention is of methods of treating diseases associated with pathological immune responses using dying or dead leukocytes which are devoid of pro-inflammatory mediators such as IL-I ⁇ , IL- 8 and MIP l ⁇ , and of devices for generating such cells and practicing such methods.
- extracorporeal photopheresis involves administering to a patient a photoactivatable pigment which can be specifically taken up by specific hematopoietic cells, such as T- cells, and subsequently harvesting blood, isolating the specific hematopoietic cells, UV-irradiating the isolated cells, and re-infusing them into the patient (United States Patent 6,219,584).
- the prior art fails to provide satisfactory methods of using dying leukocytes for treating diseases characterized by pathological immune responses.
- PCT publication WO 02/060376 to the present inventors discloses effective treatment of a systemic autoimmune disease in mammalian subjects by administration of autologous apoptotic lymphocytes.
- apoptotic cells can be used to treat autoimmune diseases with no or minimal administration of harmful and suboptimally effective anti-inflammatory drugs, as is standard practice in the art.
- Example 2 of the Examples section which follows While reducing the present invention to practice and as is described in Example 2 of the Examples section which follows, primary monocytes subjected to suspension conditions ex-vivo were found, for the first time, to undergo necrosis and to produce and secrete pro-inflammatory mediators such as IL-I ⁇ , IL-8 and MIP lot, whereas, in sharp contrast, such cells subjected to substrate-adherent conditions were found, for the first time, to undergo apoptosis in the absence of production and/or secreteion of such pro-inflammatory mediators.
- pro-inflammatory mediators such as IL-I ⁇ , IL-8 and MIP lot
- apoptotic monocytes which were obtained by inducing live leukocytes to adhere to a surface (i.e., the adherence method) are capable of inhibiting the maturation of dendritic cells and can therefore be used to maintain the peripheral tolerance to self antigens such as in autoimmunue diseases.
- prior art procedures involving ex-vivo manipulation of blood such as apheresis procedures, which inherently involve subjecting primary monocytes to suspension conditions, in fact involve induction of monocyte necrosis and concomitant secretion of pro-inflammatory mediators by such necrotic cells, and hence in fact involve introduction of potentially harmful pro-inflammatory mediators into recipients of therapeutic blood fractions obtained by apheresis.
- prior art apheresis procedures which are employed in numerous therapeutic applications, including treatment of diseases associated with pathological immune responses, such as GVHD and autoimmune diseases, may be associated with suboptimal efficacy, and harmful side-effects, such as inflammatory side-effects.
- the present invention can be used to practice apheresis to as to produce blood fractions which are depleted of pro-inflammatory mediators relative to blood fractions produced via prior art apheresis methods. Therefore, the present invention can be used to treat, via apheresis-based methods, diseases associated with pathological immune responses, such as GVHD and autoimmune diseases, with improved safety and effectiveness relative to the prior art.
- diseases associated with pathological immune responses such as GVHD and autoimmune diseases
- a method of treating a disease characterized by a pathological immune response in a subject in need thereof is effected by administering to the subject a therapeutically effective amount of a cell preparation which comprises dying or dead leukocytes which are capable of suppressing the pathological immune response and which are obtained by inducing live leukocytes to adhere to a surface.
- the method of the present invention can be used to treat in any of various types of subject, any of various diseases associated with a pathological immune response. Such diseases particularly include autoimmune diseases, transplantation- related diseases, and inflammation-associated diseases. Examples of diseases characterized by pathological immune responses which can be effectively treated according to embodiments of the present invention are described hereinbelow.
- treating when relating to a disease of the present invention refers to preventing onset of the disease, alleviating, attenuating, palliating or eliminating the symptoms of a disease, slowing, reversing or arresting the progression of the disease, or curing the disease.
- the term "disease” refers to any medical disease, disorder, condition, or syndrome, or to any undesired and/or abnormal physiological morphological, cosmetic and/or physical state and/or condition.
- the method of the present invention is used to treat the disease in a mammalian subject, such as a human subject. It will be readily appreciated that the method can be used to treat a human subject in view of its successful use in treating a systemic autoimmune disease in mice, as is described and illustrated in Example 2 of the following Examples section, and in view of the well-established extensive and relevant homologies between the human and the murine immune systems.
- the dying or dead leukocytes may be dying or dead as a result of any of various types of suitable cell death processes, according to this aspect of the present invention, the therapeutic leukocytes are preferably undergoing apoptosis. Leukocytes undergoing apoptosis are referred to herein as "apoptotic" leukocytes.
- a cell preparation containing such cells is devoid of proinflammatory mediators such as IL-l ⁇ , IL-8 and MIPIa.
- apoptotic leukocytes e.g., apoptotic or therapeutic monocytes
- proinflammatory mediators such as IL-l ⁇ , IL-8 and MIPIa.
- Apoptosis which is a distinct cell death process from necrosis, is the programmed and orderly physiological elimination of cells, occurring, for example, during normal cell and tissue development, T-lymphocyte killing of pathogen-infected cells, and self-elimination of mutationally damaged cells.
- Apoptotic cells are characterized by distinct morphologic alterations in the cytoplasm and nucleus, chromatin cleavage at regularly spaced sites, and endonucleolytic cleavage of genomic DNA at internucleosomal sites.
- Necrosis is an inherently pathological and pro-inflammatory process of cell death caused, typically but not exclusively, by the uncontrolled, progressive degradative action of enzymes following lethal cellular injury.
- Necrotic cells are typically characterized by mitochondrial swelling, nuclear flocculation, cell lysis, loss of membrane integrity, and ultimately cell death. Necrosis can be identified, by light, fluorescence or electron microscopy techniques, or via uptake of the dye trypan blue.
- the present inventors are of the opinion that cell death may be suitably induced, as in apoptosis, so as to provide signals for suppressing immune responses, and that the method of the present invention harnesses such properties of processes to achieve effective treatment of a disease of the present invention by suppressing the pathological immune response associated therewith.
- the present inventors are of the opinion that therapeutic leukocytes of the present invention can suppress immune responses directed against antigens which are included in the therapeutic leukocytes.
- necrotic cells stand in sharp contrast to those of necrotic cells, since necrosis is inherently a pathological process that is associated with generation of pro-inflammatory "danger" signals serving to stimulate ⁇ as opposed to suppress ⁇ immune responses for the body's defense.
- the term "suppressing" when relating to an immune response refers to preventing or reducing the immune response.
- the method of the present invention can be used to treat diseases which are characterized by pathological non-antigen-specific immune responses, such as non-antigen-specific inflammation in general.
- the therapeutic leukocytes may advantageously include one or more of the targeted antigens.
- therapeutic leukocytes which include such targeted antigens can be administered so as to suppress such a pathological immune response, to thereby achieve treatment of such a disease of the present invention.
- suitable therapeutic leukocytes which include targeted antigens are preferably derived from leukocytes selected endogenously expressing such targeted antigens, depending on the application and purpose, these may be alternately derived from leukocytes genetically modified to express such targeted antigens. It is well within the purview of the ordinarily skilled artisan to genetically modify leukocytes so as to induce these to include a polypeptide or nucleic acid targeted antigen. Ample guidance for genetically modifying leukocytes so as to induce such cells to include desired polypeptides or nucleic acids is provided in the literature of the art (refer, for example, to: Rossig C, Brenner MK., 2004. Genetic modification of T lymphocytes for adoptive immunotherapy. MoI Ther.
- the therapeutic leukocytes may have any one of various genotypes, depending on the application and purpose.
- the therapeutic leukocytes are syngeneic with the subject, more preferably are derived from the subject.
- subject-derived/syngeneic leukocytes will be optimal for treating a disease characterized by immune responses directed against particular subject-specific variants, or a combination of variants, of targeted autoantigens (e.g. allelic, glycosylation, and/or splice variants of polypeptide autoantigens; or sequence variants of nucleic acid autoantigens; etc.), since such combinations may be highly specific to the individual.
- syngeneic therapeutic leukocytes will avoid the risk of pro-inflammatory immune alloreactivity or xenoreactivity and concomitant stimulation of pathological immune responses inherent to the use of non-syngeneic therapeutic leukocytes, such as allogeneic or xenogeneic therapeutic leukocytes, respectively.
- the therapeutic leukocytes may be advantageously non-syngeneic with the subject, for example, where sufficient quantities of autologous therapeutic leukocytes are not available, or for treating a disease, such as allograft rejection, or alloimmune spontaneous abortion (Pandey MK. et al, 2004, Arch Gynecol Obstet. 269:161-72), involving pathological immune responses against allogeneic antigens from an allogeneic individual.
- the therapeutic leukocytes are preferably derived from the allogeneic individual, i.e.
- non-syngeneic therapeutic leukocytes are allogeneic leukocytes, most preferably allogeneic leukocytes which are haplotype-matched with the subject.
- Haplotype-matching of human subjects with allogeneic cells is routinely practiced in the art in the context of therapeutic transplantation, and usually involves matching of HLA-A, HLA-B, and HLA-DR alleles.
- the therapeutic leukocytes used to practice the method of the present invention may be derived from leukocytes of any one of various lineages, depending on the application and purpose.
- the therapeutic leukocytes are dying or dead lymphocytes (referred to hereinafter as “therapeutic lymphocytes").
- therapeutic lymphocytes dying or dead lymphocytes
- lymphocytes can be used according to the present teachings to effectively treat, without or with minimal requirement for harmful prior art administration of toxic immunosuppressive agents, a disease characterized by a pathological immune response, such as an autoimmune disease, such as a systemic autoimmune disease, such as systemic lupus erythematosus.
- a pathological immune response such as an autoimmune disease, such as a systemic autoimmune disease, such as systemic lupus erythematosus.
- the therapeutic leukocytes are dying or dead monocytes (referred to hereinafter as "therapeutic monocytes").
- the method of the present invention can employ administration of a cell preparation comprising therapeutic monocytes generated via an apheresis procedure involving adherence of monocytes to treat the disease of the present invention with enhanced safety and effectiveness relative to the prior ait methods which involve prearing the monocytes via suspension conditions.
- adherence of monocytes refers to culturing conditions which allow the adhesion of the cultured monocyte cells to a surface (e.g., a tissue culture dish, a matrix, a sac or bag with the appropriate type of nylon or plastic).
- the phrase "suspension conditions" refers to any culturing conditions which do not involve adhesion of cultured cells to a surface, such as static culturing conditions in a culture recipient having an underlying substrate with a non- cell adherent surface (e.g. non-tissue culture-treated petri, dishes), or dynamic culturing conditions, such as those involving shaking, which do not allow for static contact of cultured cells with a surface/substrate.
- the therapeutic monocytes of the present invention do not secrete pro-inflammatory mediators (see for example Figures 6a, 7a and 12a-d and Examples 2 and 6 of the Examples section which follows) and as such can be used to treat the disease characterized by a pathological immune response.
- the therapeutic leukocytes are dying or dead neutrophils (referred to hereinafter as “therapeutic neutrophils").
- therapeutic neutrophils can be used according to the present teachings to effectively treat, any of various diseases which are associated with a pathological immune response.
- the therapeutic leukocytes used to practice the method of the present invention may be derived from any lineage, or sub-lineage, of nucleated cells of the immune system and/or hematopoietic system, including but not limited to dendritic cells, macrophages, mast cells, basophils, hematopoietic stem cells, bone marrow cells, natural killer cells, and the like.
- Source leukocytes Leukocytes from which therapeutic leukocytes of the present invention may be derived (referred to hereinafter as “source leukocytes”) may be obtained in any of various suitable ways, from any of various suitable anatomical compartments, according to any of various commonly practiced methods, depending on the application and purpose, desired leukocyte lineage, etc.
- the source leukocytes are primary leukocytes, more preferably primary peripheral blood leukocytes.
- Peripheral blood leukocytes include 60 percent neutrophils, 30 percent lymphocytes, and 7 percent monocytes.
- source lymphocytes can be achieved, for example, by harvesting blood in the presence of an anticoagulant, such as heparin or citrate. The harvested blood is then centrifuged over a Ficoll cushion to isolate lymphocytes and monocytes at the gradient interface, and neutrophils and erythrocytes in the pellet.
- Leukocytes may be separated from each other via standard immunomagnetic selection or immunofluorescent flow cytometry techniques according to their specific surface markers, or via centrifugal elutriation.
- monocytes can be selected as the CD 14+ fraction
- T-lymphocytes can be selected as CD3+ fraction
- B-lymphocytes can be selected as the CD 19+ or CD22+ fraction
- neutrophils can be selected as the CD 15+ fraction.
- Lymphocytes and monocytes may be isolated from each other by subjecting these cells to substrate- adherent conditions, such as by static culture in a tissue culture-treated culturing recipient, which results in selective adherence of the monocytes, but not the lymphocytes, to the cell-adherent substrate.
- Neutrophils may be isolated from other blood cells via standard counterflow centrifugal elutriation protocols. Isolation of source monocytes is preferably performed via immunomagnetic or substrate-adherence-based selection, according to the protocols provided in the Materials and Methods section of Example 2 of the Examples section which follows.
- Therapeutic lymphocytes may suitably be derived from lymphoid tissues, such as spleen, or thymus.
- lymphoid tissues such as spleen, or thymus.
- therapeutic leukocytes derived from source splenocytes or thymocytes may be used according to the present teachings to effectively treat a disease of the present invention, such as an autoimmune disease, such as a systemic autoimmune disease, such as systemic lupus erythematosus.
- the therapeutic leukocytes may be derived from cultured primary source leukocytes, or may be derived from suitable established cell lines.
- One of ordinary skill in the art will possess the necessary expertise to suitably culture primary leukocytes so as to generate desired quantities of cultured source leukocytes of the present invention, and ample guidance for practicing such culturing methods is available in the literature of the art (refer, for example, to: Bonnard GD., 1981. Long-term cultures of immunocompetent T lymphocytes. Prog Clin Biol Res. 58:45-56; Baron CL. et al, 1999.
- Culturing of suitable source leukocytes such as leukocytes of human origin, may be performed in-vivo, for example in immune deficient hosts, such as in lines of severe combined immunodeficiency (SCID) animals.
- SCID severe combined immunodeficiency
- Suitable leukocyte cell lines may be obtained from commercial suppliers, such as the American Tissue Type Collection (ATCC).
- ATCC American Tissue Type Collection
- Established leukocyte cell lines may be particularly amenable to genetic modification, for example, to thereby include an antigen targeted by a pathological immune response of a disease of the present invention, as described hereinabove, for treatment of a disease of the present invention characterized by a pathological immune response targeted against such an antigen.
- Source leukocytes should not be obtained via a technique which will significantly interfere with their capacity to produce the therapeutic leukocytes.
- Source leukocytes may treated in any of various ways, in accordance with known prior art methods, so as to produce the therapeutic leukocytes, depending on the application and purpose.
- Apoptosis of leukocytes may be induced according to a wide variety of treatments which are well known and commonly practiced in the art. Such treatments include, but are not limited to: culturing under conditions of growth factor and/or nutrient deprivation; culturing under conditions of cellular, substrate-adherence; culturing under conditions of serum- withdrawal; irradiation, for example with UV or gamma rays; treatment with a biological apoptosis-inducing mediator, such as an activating death receptor ligand such as perforin; treatment with Fas ligand; treatment with apoptosis-inducing cells, such as immunoreactive cytotoxic T-lymphocytes (CTLs); treatment with immunosuppressive drugs such as steroids, corticosteroids, dexamethasone, cyclophosphamide, methotrexate, azathioprine, cyclosporine, staurosporine, and the like; cryotreatment; hyperthermal treatment;
- apoptosis of lymphocytes is induced by treating the primary lymphocytes with serum deprivation, a corticosteroid, or irradiation.
- inducing apoptosis of primary lymphocytes via treatment with a corticosteroid is effected by treating the primary lymphocytes with dexamethasone, more preferably with dexamethasone at a concentration of about 1 micromolar.
- inducing apoptosis of primary lymphocytes via irradiation is effected by treating the primary lymphocytes with gamma-irradiation, more preferably with a dosage of about 66 rad.
- gamma-irradiation more preferably with a dosage of about 66 rad.
- subjecting primary lymphocytes to such preferred apoptosis-inducing treatments can be used to generate therapeutic leukocytes which may be used according to the present teachings to effectively treat a disease of the present invention, such as an autoimmune disease, such as a systemic autoimmune disease, such systemic lupus erythematosus.
- an autoimmune disease such as a systemic autoimmune disease, such systemic lupus erythematosus.
- systemic erythematosus systemic lupus erythematosus.
- the term "about” refers to plus/minus 10 percent.
- apoptosis of monocytes is induced by subjecting the monocytes to in-vitro conditions of substrate/surface-adherence, as is taught for the first time in the present specification, more preferably concomitantly under conditions of serum deprivation.
- Subjecting the monocytes to in-vitro substrate/surface-adherent conditions suitable to produce therapeutic monocytes of the present invention may be suitably effected, for example, by culturing primary monocytes in tissue culture- coated tissue culture flasks under conditions of serum deprivation for a period of 40 minutes.
- such treatment results in the generation of non-pro-inflammatory apoptotic monocytes suitable for practicing the method of the present invention.
- Adherent leukocytes such as adherent monocytes
- cell- releasing compound a compound capable of facilitating release of surface-adherent cells, such as surface-adherent monocytes, and application of fluid shear flow or scraping with a suitable instrument, such as a rubber policeman, serving to release the adherent cells from the surface.
- Such suitable cell-releasing compounds and appropriate methods of their use (compound concentration, duration of exposure to compound, termination of exposure of compound, etc.), are well known and widely employed in the art.
- Such compounds include, for example, proteases, such as trypsin; and divalent cation chelators, such as EDTA.
- proteases such as trypsin
- divalent cation chelators such as EDTA.
- methods of releasing adherent cells which would normally harm or disrupt viable cells may be employed since the cells are already apoptotic and do not necessarily need to be administered as intact cell structures so as to enable disease treatment according to the method of the present invention.
- Apoptosis of source leukocytes so as to generate the therapeutic leukocytes is preferably effected in-vitro.
- apoptosis of the source leukocytes is preferably effected outside the body, i.e. ex-vivo. Alternately, apoptosis of source leukocytes may be induced in-vivolin-situ.
- Apoptosis of a cell can be confirmed by any of various commonly employed methods. Such methods include gel electrophoresis of cellular DNA to detect apoptosis-specific ladder-like DNA fragment patterns, TUNEL-staining to detect apoptosis-specific DNA fragmentation, staining with an annexin-fluorophore conjugate to detect apoptosis-specific reversal of cell membrane orientation, staining with anti-cleaved caspase-3 antibody for detection of apoptosis-specific caspase activation, microscopic inspection to detect apoptosis- specific cellular fragmentation and blebbing, and the like.
- Example 2 of the Examples section below primary monocytes were induced to undergo apoptosis by incubation in a tissue culture dish having a cell-adherent substrate.
- the present inventors have devised and implemented a novel device for inducing apoptosis of source leukocytes in-vitro.
- an apoptosis-inducing device for inducing apoptosis of leukocytes (Figure 10).
- the device 10 comprises an apoptosis-inducing chamber or chambers (each indicated by 12) selected from a chamber 14 for inducing apoptosis of monocytes (referred to hereinafter as “monocyte chamber”), a chamber 16 for inducing apoptosis of neutrophils (referred to hereinafter as "neutrophil chamber”), and/or a chamber 18 for inducing apoptosis of lymphocytes (referred to hereinafter as "lymphocyte chamber”).
- the device may comprise any of various combinations of apoptosis-inducing chambers, depending on which lineages of apoptotic leukocytes are desired.
- the monocyte chamber preferably comprises a surface 20 for enhancing adherence of monocytes thereto, a reservoir 22 for containing a medium for inducing apoptosis of monocytes (referred to hereinafter as "monocyte medium”), and/or a mechanism 28 for resuspending surface-adherent monocytes (referred to hereinafter as "cell-adherent surface”), more preferably all of which.
- monocyte medium a medium for inducing apoptosis of monocytes
- cell-adherent surface resuspending surface-adherent monocytes
- the cell-adherent surface is hydrophilic and negatively charged, and may be obtained in any of various ways known in the art, preferably by modifying a polystyrene surface using, for example, corona discharge, or gas-plasma. These processes generate highly energetic oxygen ions which graft onto the surface polystyrene chains so that the surface becomes hydrophilic and negatively charged, thereby facilitating cellular adherence thereto.
- Suitable cell-adherent surfaces for inducing leukocyte apoptosis according to the present invention may be provided by any one of various tissue-culture-treated tissue culture recipients designed for facilitating cell-adherence thereto which are available from various commercial suppliers (e.g. Corning, Perkin-Elmer, Fisher Scientific, Evergreen Scientific, Nunc, etc.).
- the monocyte chamber may comprise any of various suitable mechanisms for resuspending surface-adherent monocytes, so as to enable the harvesting thereof.
- Suitable mechanisms for such purpose include any combination of: a reservoir for containing a cell-releasing compound of the present invention, and a mechanism for introducing the cell-releasing compound into the monocyte chamber; a flow- generating mechanism for generating in the monocyte chamber a flow of sufficient force and direction for resuspending the surface-adherent monocytes, and a mechanism of controlling the operation of the flow-generating mechanism; and a scraping mechanism for scraping the surface-adherent monocytes off the cell-adherent surface of the monocyte chamber, and a mechanism for controlling the operation of the scraping mechanism.
- Suitable flow-generating mechanisms for facilitating resuspension of surface- adherent cells include for example, magnetic stirrers, and fluid mixing mechanisms based on rotating propeller blades.
- a suitable scraping mechanism for scraping the surface-adherent monocytes off the cell-adherent surface of the monocyte chamber is an automated rubber policeman.
- the neutrophil chamber comprises a reservoir 24 for containing a medium for inducing apoptosis of neutrophils (referred to hereinafter as "neutrophil medium").
- the lymphocyte chamber comprises a reservoir 26 for containing a medium for inducing apoptosis of lymphocytes (referred to hereinafter as "lymphocyte medium").
- lymphocyte medium a medium for inducing apoptosis of lymphocytes
- each apoptosis-inducing chamber may be configured so as to comprise an apoptosis-inducing mechanism 30 selected from the group consisting of: an irradiating mechanism for inducing apoptosis, a mechanical mechanism for inducing apoptosis, and a chemical or biochemical substance or environment for inducing apoptosis.
- an apoptosis-inducing mechanism 30 selected from the group consisting of: an irradiating mechanism for inducing apoptosis, a mechanical mechanism for inducing apoptosis, and a chemical or biochemical substance or environment for inducing apoptosis.
- each apoptosis inducing chamber is preferably equipped with a temperature control mechanism enabling maintenance of leukocytes at a desired temperature, and is further preferably equipped with a mechanism for maintenance of carbon dioxide air levels appropriate to the particular cell medium employed.
- each apoptosis-inducing chamber is preferably equipped with a fluid inlet 32 and a valve for controlling fluid flow therethrough, and a fluid outlet 34 and a valve for controlling fluid flow therethrough.
- the device is configured so as to enable introduction of each lymphocytes, monocytes, and/or neutrophils into respective chambers configured so as to induce apoptosis thereof according to the teachings of the present invention, and is configured so as to enable harvesting of such leukocytes from such chambers for administration for disease treatment according to the method of the present invention.
- Treatment of a disease characterized by a pathological immune response according to the method of the present invention may be effectively practiced, depending on the application and purpose, by administering to the subject according to any of various suitable administration regimens a therapeutically effective amount of any of various suitable types of cell preparation which comprise therapeutic leukocytes of the present invention.
- disease treatment may be effectively practiced by administering to the subject a therapeutically effective amount of a cell preparation which may comprise any of various combinations of therapeutic leukocyte lineages.
- a cell preparation which may comprise any of various combinations of therapeutic leukocyte lineages. Examples of specific treatment protocols which may be used for treatment of various diseases via administration of therapeutic lymphocytes, therapeutic monocytes, and/or therapeutic neutrophils of the present invention are provided in Examples 3, 4 and 5 of the Examples section which follows, respectively.
- administration of therapeutic lymphocytes is used to treat an autoimmune disease.
- the autoimmune disease is a systemic autoimmune disease, more preferably systemic lupus erythematosus.
- administration of combined therapeutic lymphocytes, monocytes, and neutrophils may be used to treat graft-versus-host disease.
- treatment of a disease of the present invention is effected by administering to the subject a cell preparation which comprises a total dose of about 200 million therapeutic leukocytes per kilogram body weight.
- a total dose is administered as unit doses of about 40 million cells per kilogram body weight, and/or is administered as unit doses at weekly intervals, more preferably both of which.
- Suitable total doses according to this embodiment include total doses of about 20 million to about 2 billion cells per kilogram body weight, more preferably about 40 million to about 1 billion cells per kilogram body weight, more preferably about 80 million to about 500 million cells per kilogram body weight, and more preferably about 160 million to about 250 million cells per kilogram body weight.
- Suitable unit doses include unit doses of about 4 million to about 400 million cells per kilogram body weight, more preferably about 8 million to about 200 million cells per kilogram body weight, more preferably about 16 million to about 100 million cells per kilogram body weight, and more preferably about 32 million to about 50 million cells per kilogram body weight.
- the therapeutic leukocytes are administered to the subject systemically, more preferably via the intravenous route.
- the therapeutic leukocytes may be administered to the subject according to any of various other routes, including, but not limited to, the parenteral, intraperitoneal, intramuscular, subcutaneous, oral, transnasal and rectal routes.
- the therapeutic leukocytes are administered to the subject suspended in a suitable physiological buffer, such as saline solution, PBS, HBSS, and the like.
- a disease of the present invention (systemic lupus erythematosus) was effectively treated in a mouse (average weight 0.025 kilograms) by intravenous administration of 5 doses of one million therapeutic lymphocytes at weekly intervals, which corresponds to the aforementioned preferred total and unit doses of 200 million and 40 million cells per kilogram body weight, respectively.
- disease treatment may be advantageously effected according to the teachings of the present invention in conjunction with standard prior art therapies, and/or by co-administration of an immunosuppressive molecule, such as IL-IO or TGF-beta.
- disease status will preferably be closely monitored so as to optimize and suitably modify the treatment.
- levels of any of various proinflammatory cytokines, cliemoldnes or other molecules may be monitored in the patient to facilitate monitoring of disease treatment.
- tissue levels of relevant autoantibodies may be measured for monitoring disease treatment.
- systemic autoimmune disease such as systemic lupus erythematosus
- autoantibodies include those specific for double- stranded DNA, and those specific for phospholipids .
- One of ordinary skill in the art such as a physician, preferably a specialist in the disease to be treated, will possess the necessary expertise for applying the teachings of the present invention so as to effectively treat a disease of the present invention in a human subject.
- the present inventors have devised a novel disease treatment device which can harvest blood from the subject, generate desired therapeutic leukocytes from the harvested blood, and re-infuse the therapeutic leukocytes to the subject.
- the disease-treatment device 40 comprises a pump 42 for pumping blood from a subject into the device and returning blood to the subject from the device; a leukocytes separator 44 in communication with the pump for separating circulating leukocytes from whole blood; and the apoptosis-inducing device 10 of the present invention in communication with the leukocytes separator for inducing apoptosis of the leukocytes, and further in communication with the pump for administering the apoptotic leukocytes to the subject.
- the disease-treatment device of the present invention is configured essentially as a prior art blood cell apheresis device capable of harvesting blood from a subject, isolating blood cells, subjecting the isolated cells to a given treatment, and re-infusing the treated cells back into the subject.
- Such prior art devices are widely used, for example, for practicing CD34+ cell leukapheresis, or leukocyte photopheresis.
- the disease-treatment device of the present invention comprises the novel and inventive feature of including the apoptosis-inducing device of the present invention for inducing apoptosis, in accordance with the method of the present invention, of separated leukocytes prior to their re-infusion into the subject.
- leukocyte apheresis devices such as the disease-treatment device of the present invention, and their use, is provided in the literature of the art (refer, for example, to: Burgstaler EA. et al, 2004. Hematopoietic progenitor cell large volume leukapheresis (LVL) on the Fenwal Amicus blood separator. J Clin Apheresis. 19:103-11; Schwella N. et al, 2003. Comparison of two leukapheresis programs for computerized collection of blood progenitor cells on a new cell separator. Transfusion. 43(l):58-64; Kohgo Y. et al, 2002.
- LDL Hematopoietic progenitor cell large volume leukapheresis
- Leukocyte apheresis using a centrifugal cell separator in refractory ulcerative colitis a multicenter open label trial.
- the disease-treatment device of the present invention presents various advantages over prior art apheresis devices used for disease treatment.
- the device particularly enables practicing of photopheresis for treatment of diseases characterized by pathological immune responses with greater safety and effectiveness relative to the prior art since it avoids generation of pro-inflammatory leukocyte necrosis inherent to prior art devices, by virtue of enabling non-pro-inflammatory leukocyte apoptosis, such as monocyte and neutrophil apoptosis.
- Embodiments of the present invention can be used to treat any of various diseases characterized by a pathological immune response.
- the disease is an autoimmune disease or a transplantation-related disease.
- the autoimmune disease is a systemic autoimmune disease and/or an antibody-mediated autoimmune disease.
- the autoimmune disease is systemic lupus erythematosus (SLE).
- the transplantation-related disease is graft-versus-host disease (GVHD).
- GVHD graft-versus-host disease
- the disease characterized by a pathological immune response may be any of various inflarnmatory/inflammation-associated diseases.
- the present invention can be used to treat a disease which is characterized by a pathological immune response in any of various anatomical compartments of the body.
- antibody-mediated autoimmune diseases include but are not limited to rheumatoid diseases, rheumatoid autoimmune diseases, rheumatoid arthritis
- paraneoplastic neurological diseases cerebellar atrophy, paraneoplastic cerebellar atrophy, non-paraneoplastic stiff man syndrome, cerebellar atrophies, progressive cerebellar atrophies, encephalitis, Rasmussen's encephalitis, amyotrophic lateral sclerosis, Sydeham chorea, Gilles de Ia Tourette syndrome, polyendocrinopathies, autoimmune polyendocrinopathies (Antoine JC. and Honnorat J. Rev Neurol (Paris) 2000 Jan; 156 (1):23); neuropathies, dysimmune neuropathies (Nobile-Orazio E.
- vasculitises necrotizing small vessel vasculitises, microscopic polyangiitis, Churg and Strauss syndrome, glomerulonephritis, pauci-immune focal necrotizing glomerulonephritis, crescentic glomerulonephritis (Noel LH. Ann Med Interne (Paris). 2000 May;151 (3):178); antiphospholipid syndrome (Flamholz R. et al, J Clin Apheresis 1999;14 (4): 171); heart failure, agonist-like beta-adrenoceptor antibodies in heart failure (Wallukat G. et al, Am J Cardiol.
- organ/tissue specific autoimmune diseases comprise cardiovascular diseases, rheumatoid diseases, glandular diseases, gastrointestinal diseases, cutaneous diseases, hepatic diseases, neurological diseases, muscular diseases, nephric diseases, diseases related to reproduction, connective tissue diseases and systemic diseases.
- autoimmune cardiovascular diseases comprise atherosclerosis (Matsuura E. et al, Lupus. 1998;7 Suppl 2:S135), myocardial infarction (Vaarala O. Lupus. 1998;7 Suppl 2:S132), thrombosis (Tincani A. et al, Lupus 1998;7 Suppl 2:S107-9), Wegener's granulomatosis, Takayasu's arteritis, Kawasaki syndrome (Praprotnik S. et al, Wien Klin Klin Klin Klinschr 2000 Aug 25;112 (15-16):660), anti- factor VIII autoimmune disease (Lacroix-Desmazes S.
- autoimmune hemolytic anemia Efremov DG. et al, Leuk Lymphoma 1998 Jan;28 (3- 4):285; Sallah S. et al, Ann Hematol 1997 Mar; 74 (3):139
- cardiac autoimmunity in Chagas' disease Cunha-Neto E. et al, J Clin Invest 1996 Oct 15;98 (8):1709
- anti-helper T lymphocyte autoimmunity Caporossi AP. et al, Viral Immunol 1998;11 (1):9.
- autoimmune rheumatoid diseases comprise rheumatoid arthritis
- autoimmune glandular diseases comprise pancreatic disease
- Type I diabetes thyroid disease, Graves' disease, thyroiditis, spontaneous autoimmune thyroiditis, Hashimoto's thyroiditis, idiopathic myxedema, ovarian autoimmunity, autoimmune anti-sperm infertility, autoimmune prostatitis and Type I autoimmune polyglandular syndrome, diseases comprise autoimmune diseases of the pancreas, Type 1 diabetes (Castano L. and Eisenbarth GS. Ann. Rev. Immunol. 8:647; Zimmet P. Diabetes Res Clin Pract 1996 Oct;34 Su ⁇ l:S125), autoimmune thyroid diseases, Graves' disease (Orgiazzi J. Endocrinol Metab Clin North Am 2000 Jun;29 (2):339; Sakata S.
- autoimmune gastrointestinal diseases comprise chronic inflammatory intestinal diseases (Garcia Herola A. et al , Gastroenterol Hepatol. 2000 Jan;23 (1):16), celiac disease (Landau YE. and Shoenfeld Y. Harefuah 2000 Jan 16;138 (2):122), colitis, ileitis and Crohn's disease.
- autoimmune cutaneous diseases comprise autoimmune bullous skin diseases, such as, but not limited to, pemphigus vulgaris, bullous pemphigoid and pemphigus foliaceus, discoid lupus erythematosus.
- autoimmune hepatic diseases comprise hepatitis, autoimmune chronic active hepatitis (Franco A. et al, Clin Immunol Immunopathol 1990 Mar;54 (3):382), primary biliary cirrhosis (Jones DE. Clin Sci (Colch) 1996 Nov;91 (5):551; Strassburg CP. et al, Eur J Gastroenterol Hepatol. 1999 Jun;l l (6):595) and autoimmune hepatitis (Manns MP. J Hepatol 2000 Aug;33 (2):326).
- autoimmune neurological diseases comprise multiple sclerosis
- autoimmune muscular diseases comprise myositis, autoimmune myositis and primary Sjogren's syndrome (Feist E. et al, Int Arch Allergy Immunol 2000 Sep;123 (1):92) and smooth muscle autoimmune disease (Zauli D. et al, Biomed Pharmacother 1999 Jun;53 (5-6):234).
- autoimmune nephric diseases comprise nephritis and autoimmune interstitial nephritis (Kelly CJ. J Am Soc Nephrol 1990 Aug;l (2): 140).
- autoimmune diseases related to reproduction comprise repeated fetal loss (Tincani A. et al, Lupus 1998;7 Suppl 2:S 107-9).
- autoimmune connective tissue diseases comprise ear diseases, autoimmune ear diseases (Yoo TJ. et al, Cell Immunol 1994 Aug;157 (1):249) and autoimmune diseases of the inner ear (Gloddek B. et al, Ann N Y Acad Sci 1997 Dec 29;830:266).
- systemic autoimmune diseases comprise systemic lupus erythematosus (Erikson J. et al, Immunol Res 1998;17 (l-2):49) and systemic sclerosis (Renaudineau Y. et al, Clin Diagn Lab Immunol. 1999 Mar;6 (2):156); Chan OT. et al, Immunol Rev 1999 Jun;169:107).
- transplantation-related diseases include, but are not limited to, graft rejection, chronic graft rejection, subacute graft rejection, hyperacute graft rejection, acute graft rejection and graft- versus-host disease (GVHD).
- graft rejection chronic graft rejection
- subacute graft rejection hyperacute graft rejection
- acute graft rejection graft- versus-host disease
- inflammatory/inflammation-associated diseases include, but are not limited to, restenosis following percutaneous transluminal coronary angioplasty (PTCA), restenosis following PTCA with stent implantation, myocardial infarction, inflammation associated with mechanical injury, neurodegenerative diseases, ulcers, prosthetic implants, menstruation, septic shock, anaphylactic shock, toxic shock syndrome, cachexia, gangrene, musculo-skeletal inflammation, idiopathic inflammation.
- PTCA percutaneous transluminal coronary angioplasty
- the devices and methods of the present invention can be used to treat a broad range of diseases associated with pathological immune responses, such as autoimmune diseases, transplantation-related diseases and inflammatory/inflammation-related diseases, with improved safety and effectiveness relative to prior art methods which involve administration of harmful immunosuppressive drugs, and/or which inherently and unknowingly involve counterproductive and harmful administration of pro-inflammatory mediators, as is presently taught for the first time in the art.
- diseases associated with pathological immune responses such as autoimmune diseases, transplantation-related diseases and inflammatory/inflammation-related diseases
- Autoimmune diseases such as systemic lupus erythematosus (SLE)
- SLE systemic lupus erythematosus
- An optimal strategy for treating such diseases would be to present targeted antigens to the immune system of an individual afflicted with such a disease in such a way as to induce tolerance to such antigens by the immune system of the individual.
- An optimal way to achieve this goal would be to employ autologous apoptotic cells, which would obviate or minimize the necessity for administration of toxic immunosuppressive agents, the standard means of treatment in the art.
- Thymocytes and splenocytes were prepared from 4 to 8 week-old mice according to standard methodology. Apoptosis of thymocytes or splenocytes was induced by either serum deprivation, 1 micromolar dexamethasone, or gamma-irradiation (66 rad). Apoptosis was confirmed via flow cytometric analysis of annexin-FITC staining, DNA fragmentation and propidium iodide staining of fragmented DNA.
- Treatment protocol MRL/MpJ-Fas lpr and C3H-SnJ mice obtained from Jackson Laboratories, Bar Harbor, ME, were administered a total of 5 x 10 6 syngeneic sex- and age-matched apoptotic cells per mouse, as 5 weekly injections of 1 x 10 6 cells per mouse.
- the route of administration was intravenous injection into the tail vein of cells suspended in a volume of 200 microliters.
- As negative controls syngeneic, sex- and age-matched mice were injected with vehicle (saline) only.
- Autoimmune response - anti-self DNA antibody ELISA Serum samples were obtained immediately prior to treatment and at two-week intervals following treatment. The immune response was evaluated by quantifying serum antibodies specific for single-stranded DNA (ssDNA) and double-stranded DNA (dsDNA) by enzyme-linked immunosorbent assay (ELISA) of 100-fold diluted serum.
- ssDNA single-stranded DNA
- dsDNA double
- MRL/MpJ-Fas lpr mouse model was used to analyze the effects of administration of syngeneic apoptotic lymphocytes on disease pathogenesis.
- MRL/MpJ-Fas pr mice develop SLE-like disease due to mutation in Fas, a receptor that mediates apoptosis and activation of induced cell death of the immune system. Since in SLE patients, as well as in MRL/MpJ-Fas lpr mice, the development of autoantibodies and kidney disease are the most specific pathophysiological parameters, those parameters were evaluated in MRL/MpJ-Fas lpr mice following administration of apoptotic cells. Two groups of age- and sex-matched MRL/MpJ-Fas lpr mice were compared.
- mice 1 x 10 6 syngeneic apoptotic cells were injected intravenously into each of five mice, five times at weekly intervals, for a total. dose of 5 x 10 6 cells per mouse.
- 200 microliters of saline carrier alone was injected.
- IgG anti-ssDNA levels were then measured via ELISA at two-week intervals and were found to be comparable in both groups prior to treatment, with a mean O.D. value of 0.096 plus/minus 0.018 ( Figure 1).
- mice administered with vehicle alone displayed, as expected in mice which develop lupus- like disease, increased anti-ssDNA antibody levels, as evidenced by an ELISA O.D.
- mice injected with 1 x 10 6 syngeneic apoptotic cells unexpectedly had significantly reduced levels of autoantibodies, with an ELISA O.D. value obtained of 0.193 plus/minus 0.017 (p ⁇ 0.0001, student t-test).
- serum samples from the control and experimental groups were evaluated at 2-week intervals for IgM. The ELISA O.D.
- mice injected with saline were 0.198 plus/minus 0.017, 0.205 plus/minus 0.02, 0.300 plus/minus 0.033 and 0.378 plus/minus 0.037; and for mice treated with apoptotic cells were 0.108(+0.03), 0.170(+0.07), 0.186(+0.04) and 0.203(+0.8).
- mice treated with apoptotic cells were 0.108(+0.03), 0.170(+0.07), 0.186(+0.04) and 0.203(+0.8).
- Statistical analysis indicated that was no significant difference between the two groups.
- anti- ssDNA IgG levels were unexpectedly found to significantly decrease following injection of apoptotic cells, with ELISA O.D.
- anti-dsDNA antibody titers were measured immediately prior to treatment, and 6-8 weeks post-treatment, when the mice were sacrificed. As shown in Figure 2, anti-dsDNA antibody titers were surprisingly found to be significantly reduced (p ⁇ 0.00) in mice injected with apoptotic cells. An average O.D. value of 0.599 plus/minus 0.026 was obtained in an anti-dsDNA antibody ELISA of serum from mice injected with saline, and an average O.D. value of 0.358 plus/minus 0.038 was obtained in mice injected with the apoptotic cells.
- mice injected with saline displayed significant elevations in proteinuria and hematuria and concomitant glomerular disease, as shown in Table 1.
- mice injected with the apoptotic cells overall unexpectedly displayed significantly decreased proteinuria and hematuria and concomitant glomerular disease, consistent with the serological response. Strikingly, in two out of five mice treated with apoptotic cells, no deterioration or very slight deterioration was noticed.
- Table 1 C3H/SnJ, normal mice. "+”, normal proteinuria. "-”, normal hematuria. Pathological index is proportional to the number of plus signs.
- PRODUCTION METHOD OF IMPROVING PRIOR ART APHERESIS
- Immune/hematological. diseases such as graft- versus-host disease (GVHD)
- GVHD graft- versus-host disease
- the optimal strategy for treating such diseases involves performing apheresis procedures.
- apheresis procedures involve removing blood from an individual, separating the blood into fractions and performing therapeutic treatment of specific fractions, removing undesirable pathological fractions and reinfusing the remainder to the individual, or harvesting desired may be associated with undesirable side-effects and/or suboptimal effectiveness.
- a potentially optimal strategy for performing apheresis involves identifying harmful effects of apheresis procedures on blood components so as to enable design of optimal methods and devices for performing apheresis. While reducing the present invention to practice, as described below, the induction of necrosis of monocytes, and the concomitant secretion of harmful pro-inflammatory mediators thereby resulting from their ex-vivo suspension, as typically occurs during apheresis procedures was unexpectedly uncovered, as opposed to serum deprivation and substrate-adherent conditions which were surprisingly found to induce apoptosis of monocytes, in the absence of the aforementioned secretion of pro-inflammatory mediators.
- Human mononuclear cells were isolated from heparinized peripheral blood by density gradient centrifugation. The isolated mononuclear cells were separated into monocyte, B-cell and T-cell populations by positively selecting monocytes as the CD 14+ fraction by magnetic bead separation (Miltenyi Biotec, Auburn, CA, USA), positively selecting B-cells as the CD22+ fraction, and negatively selecting T-cells as the CD14-CD22- fraction. Purity was greater than 95 percent for monocytes, greater than 95 percent for B-cells and greater than 88 percent for T-cells.
- Polymorphonuclear cells were separated by density gradient centrifugation of the upper fraction obtained following incubation of peripheral blood with Plasmasteril (GmbH, Bad Homburg, Germany). When necessary, red blood cells in the pellets were hemolysed under hypoosmotic conditions. Anti-CD 15 magnetic beads were employed to purify neutrophils to greater than 95 percent purity. Alternately, monocyte isolation was performed concomitantly with apoptosis induction by adherence, as described below.
- Leukocyte death was induced by serum deprivation or suspension, and necrosis of leukocytes was fas-induced.
- monocytes were incubated at 37 degrees centigrade in serum-free RPMI culture medium in polypropylene tubes.
- Necrosis was induced hyperthermally by incubation at 56 degrees centigrade for 20 minutes, and confirmed by greater than 95 percent trypan blue positive cells and swollen cells detected via flow cytometry forward-scatter.
- Monocyte apoptosis was induced via substrate-adherence + serum withdrawal by either of two methods.
- monocytes isolated using anti-CD 14 conjugated magnetic beads (Miltenyi Biotech, Bergisch Gladbach, Germany) were incubated in serum-free RPMI at a concentration of 7.5 million to 20 million cells per milliliter in 35 mm diameter tissue culture-treated Petri dishes (Corning, USA, Cat. No. 430165).
- isolated PBMCs were incubated in serum-free RPMI at a concentration of 15 million to 30 million cells per milliliter in 35 mm diameter tissue culture-treated Petri dishes (Corning, USA, Cat. No. 430165), and after 40 minutes, non-adherent cells were washed away, leaving behind the adherent, apoptotic monocytes.
- Cell death inhibition assays In some of the experiments the cells were pretreated or co-treated (as indicated) with different reagents to achieve cell death inhibition.
- anti-Fas inhibitory mAb ZB4 MBL, Nagoya, Japan
- anti-Fas mAb DM542A Acris Antibodies, Hiddenhausen, Germany
- Caspase-1 was inhibited using caspase-1 (ICE) fink inhibitor Z-WEHD (R & D Systems).
- proteasome inhibition cells were exposed for 45 minutes to 50 micromolar of the proteasome inhibitor MGl 32 (Calbiochem, San ' Diego, CA, USA).
- P38 and JNK were inhibited using 10 micromolar SB203580 (Calbiochem, Darmstadt, Germany) or 20 millimolar L-JNKIl (Alexis, San Diego, CA, USA), respectively.
- 10 micromolar SB203580 Calbiochem, Darmstadt, Germany
- 20 millimolar L-JNKIl Alexis, San Diego, CA, USA
- For transcription inhibition 5 micrograms/ml Actinomycin D was used and for translation inhibition, 15 micrograms/ml cycloheximide (Sigma, St. Louis, MO, USA) was used.
- Monocyte activation was induced with 500 micrograms/ml, 1 mg/ml Zymosan, or 1 microgram/ml of LPS (Sigma, St. Louis, MO, USA).
- GEArray gene expression array systems hGEA9912090, hGEA9913030 and liGEA9913040 (SuperArray, Bethesda, MD 5 USA) were used. Each array consists of 56 coordinates containing specific cDNA fragments spotted in duplicates as well as control sequences [PUC 18 as negative control; beta-actin and glyceraldehyde-3- phosphate dehydrogenase (GAPDH) as positive control].
- cDNA probes were synthesized from total RNA samples using the manufacturer's primer mix as a reverse transcriptase primer. The cDNA probes were hybridized to gene-specific cDNA fragments spotted on the membranes. The relative expression level of the genes was adjusted based on intensity of hybridization signals to the housekeeping genes beta- actin and GAPDH, then gene expression was quantified by scanning densitometry. Each experiment was performed at least three times to ensure reproducibility of results.
- Cytokine/chemokine analysis concentrations of the cytokines/chemokines IL- 4, IL-6, IL-8, IFN-gamma, TNF-alpha, TGF-beta, and MIP-I -alpha, were determined via ELISA immunoassay (R&D systems, Minneapolis, MN, USA) according to the instructions provided by the manufacturer.
- CD 14+ monocytes were isolated and subjected to either substrate-adherence + serum deprivation, or suspension + serum deprivation. Surprisingly, substrate adherence and serum deprivation resulted in apoptosis of the cells (Figure 3) with no decline in cell numbers for the first 10 hours, whereas suspension + serum withdrawal resulted in very rapid death with 50 percent reduction in cell numbers reached in 4 hours ( Figure 4). Very few suspended monocytes did not stain positive for propidium iodide, and from the start of suspension most of the cells were found to be positive for both annexin-V and propidium iodide in constant proportion ( Figure 4), exhibited low levels of hypodiploid staining (not shown), and displayed a sharp decline in cell numbers.
- Tests performed to determine whether this transcriptional activity produced secreted proteins revealed production of high levels of IL-1-beta ( Figure 6a), IL-8 (320 plus/minus 64 pg/ml), and MIP-I- alpha (320 plus/minus 64 pg/ml) that were specific to monocytes but not to neutrophils undergoing suspension. No mRNA of IL-4, IL-10, IFN-gamma, and TGF-beta was detected. As controls, tests were performed for detection of IL-4, IL- 10, IFN-gamma, and TGF-beta protein production (Quantikine, R&D Systems).
- IL-10 was found to be secreted, at 50-100 ng/ml, following proinflammatory cytokine secretion, peaking at 24 hours after the start of suspension.
- magnetically isolated monocytes subjected to surface adherence and serum withdrawal did not secrete IL-1-beta (or any pro-inflammatory cytokines) (Figure 6a) and were capable of inducing tolerance in dendritic cells (not shown).
- treatment of the cells with the transcription inhibitor actinomycin D, or the translation inhibitor cycloheximide dramatically inhibited cytokine secretion by monocytes subjected to suspension + serum withdrawal.
- monocytes that were allowed to adhere during serum withdrawal did not show any production of pro-inflammatory cytokines (not shown). Furthermore, monocytes that were allowed to adhere and were triggered to die by other methods of induction of apoptosis such as staurosporine, cyclophosphamide, Fas ligand, and more, always kept their non-inflammatory mode of death (not shown).
- IL-I -beta The cytokine IL-I -beta is the key initiator of the innate immunity acute inflammatory response [21, 22].
- LPS lipopolysaccharide
- IL-I -beta is synthesized in human monocyte-lineage cells as the biologically inactive 31 IcDa precursor pro-IL-1-beta.
- IL-I -beta is not secreted through the classical endoplasmic reticulum-Golgi pathway [23] due to a lack in the N-terminal amino acid leader sequence that would allow translation at the endoplasmic reticulum associated ribosomes and subsequent packaging into secretory vesicles.
- IL-I -beta is also not stored in or released from exocytotic granules [24].
- pro-IL-1-beta In order to be released as biologically active 17 kDa IL-I -beta, pro-IL-1-beta must be further proteolytically cleaved by caspase-1, which undergoes activation from its pro-caspase zymogenic form. Activation of P2X7 receptors by extra cellular ATP following NFkappaB activation causes phosphatidylserine (PS) flip in the plasma membrane and loss of membrane asymmetry with respect to its positioning. Readily releasable phosphatidylserine-exposing micro-vesicles containing 17 kDa IL-I -beta are then pinched off from the cell within a few seconds [25].
- PS phosphatidylserine
- Monocytes were recently shown to exhibit pro-inflammatory signaling following Fas-induced apoptosis [28].
- human monocytes displayed Fas- dependent IL-8 and TNF-alpha secretion, which was associated with NFkappaB activation and shown to occur even in the absence of apoptosis [29].
- NFkappaB activation was not detected in monocytes subjected to suspension-induced death ( Figures 8a-c).
- monocytes undergoing, apoptosis were exposed to two different Fas inhibiting antibodies.
- pro-inflammatory IL-I -beta, IL-8, MIP-I -alpha, MIP-I -beta, IL- 6 and IL- l ⁇ were all produced and secreted at significant levels and in a transcriptional- and translational-dependent pattern in monocytes subjected to suspension-induced death but not from adherence-serum deprived monocytes.
- the cells showed a necrotic pattern with rapid lysis and their death was neither caspase- nor Fas-dependent.
- Apoptotic cells have been shown to signal neighboring cells in a variety of ways.
- Pro-phagocytic signals on apoptotic cells serve as markers for phagocytes to specifically recognize the apoptotic cells and subsequently ingest them. Such signals can appear on the membrane of apoptotic cells.
- Direct signals include alterations in cell surface phospholipid composition [32], changes in cell surface glycoproteins, or in surface charge [33].
- certain serum proteins can opsonize an apoptotic cell surface, and signal to phagocytes to engulf the opsonized apoptotic cells [34, 35].
- viable cells express phagocytosis-inhibitory signals by restriction of phosphatidylserine to the inner leaflet of the plasma membrane or CD31 expression [36].
- Apoptotic cells can also secrete molecules which are important for recruitment of phagocytic cells, phagocytosis, and immune responses in the immediate milieu. Examples of mediators of immune suppression and phagocyte recruitment include TGF-beta [37] and phosphoisocholine [38]. Most of these mechanisms have suggested that there occurs efficient identification and clearance of apoptotic cells, in processes leading to non-inflammatory and non- autoimmune consequences [11, 12].
- Monocytes were shown here to be capable of generating pro-inflammatory cytokines/chemokines when subjected to suspension- induced controlled necrosis. As such monocytes may have a unique and crucial role in host defense, in autoimmunity, and in the generation of inflammation. In monocytes, pro-inflammatory cytokines/chemokines may induce cross-priming, whereas anti-inflammatory cytokines may induce cross-tolerization. Based on earlier studies, it was hypothesized that expression of Fas ligand
- FasL FasL
- FasL enables cells to counterattack the immune system, and that transplant rejection, for example, could be prevented by expressing Fas ligand on transplanted organs. More recent studies have indicated that the notion of Fas ligand as a mediator of immune privilege needed to be reconsidered, and in fact Fas ligation may be pro- inflammatory [28].
- Fas was proposed to mediate pro-inflammatory cytokines such as IL-I -beta [39] and recently it has been suggested that, following anti-Fas (CHl l)-induced apoptosis, human monocytes produced Fas-dependent IL- 8 and TNF- alpha secretion, which was associated with NFkappaB activation, and was shown to occur in macrophages even in the absence of apoptosis [29].
- CHl l anti-Fas
- TNF- alpha secretion which was associated with NFkappaB activation, and was shown to occur in macrophages even in the absence of apoptosis [29].
- the presently disclosed experimental results reveal for the first time a novel, non-Fas-dependent, non-caspase dependent pattern of pro-inflammatory cytoldne/chemokine secretion that is associated with MAPK activation in monocytes subjected to suspension-induced controlled necrosis.
- MAPKs are divided into three major groups: ERKs, JNKs/stress-activated protein kinases, and p38, based on their degree of homology, biological activities, and phosphorylation motifs.
- JNK may contribute to death receptor transcription-dependent apoptotic signaling via c-Jun/AP-1, leading to transcriptional activation of FasL.
- monocytes secrete piO-inflammatory cytokines either in Fas-dependent or p38-dependent patterns.
- monocytes are unique among leukocytes in their p38-dependent cytokine/chemokine secretion, and as such sustained activation of p38 may determine immune response in homeostasis, infection, inflammation, and autoimmunity.
- human monocytes but not neutrophils or resting B- or T-lymphocytes, undergo controlled necrosis and release high amounts of the pro-inflammatory cytokines IL-1-beta, IL-8, MIP-I -alpha, MIP-I -beta, IL-6 and IL- l ⁇ under non-substrate-adherent (suspension) conditions, and thereby create a pro-inflammatory milieu.
- IL-1-beta secretion involves a signaling cascade that is completely distinct from the cascade seen upon monocyte activation or Fas signaling, is associated with p38 phosphorylation and is completely abrogated upon exposure of monocytes to p38 inhibitor.
- This distinct cascade may, on the one hand, help cross-priming upon infection, but on the other hand it may expose the body to persistent inflammatory and/or autoimmune response triggered by self-antigens that are derived from apoptotic monocytes in the context of pro-inflammatory cytokines and chemokines.
- death of different freshly isolated leukocytes such as neutrophils, monocytes, and lymphocytes, occurs via different modes and with different kinetics, under similar conditions, resulting in totally different immune responses.
- Apoptotic lymphocytes have an immunosuppressive, tolerizing, and anti- inflammatory effect provided they are isolated in the right way and therapeutically in the right conditions and if mixed with other cells, only in controlled way (which does not occur spontaneously in leukocytes from the blood). Described below are methods of suitably obtaining and administering apoptotic lymphocytes for treatment of various disease conditions.
- lymphocyte apoptosis by one or more of the following methods:
- apoptotic lymphocytes via one of the following routes: parenterally, intravenously, intramuscularly, subcutaneously, intra- dermally, and orally. 6. Repeat the procedure according to disease or indication.
- the cell dosages described below are suitable for a 70 kg patient and may be adjusted according to body weight.
- Treatable autoimmune diseases include rheumatoid arthritis, idiopathic polyarthritis, multiple sclerosis, inflammatory bowel disease, scleroderma, Sjogren's syndrome, polymyositis or dermatomyositis, systemic or localized vasculitis, celiac disease, Guillain-Barre syndrome, myasthenia gravis, diabetes mellitus type I, antiphospholipid syndrome, thyroiditis. Grave's disease, and psoriasis. Can be used for treating active disease or preventing flares. Administer 10 million to 5 billion cells every 2-4 weeks, as needed.
- FMF familial Mediterranean fever
- EXAMPLE 4 THERAPEUTIC USAGE OF APOPTOTIC MONOCYTES Apoptotic monocytes have an immunosuppressive, tolerizing, and antiinflammatory effect provided they are isolated and therapeutically administered in the right way. Otherwise they may undergo pro-inflammatory necrosis. Described below are methods of suitably obtaining and administering apoptotic monocytes for treatment of various disease conditions.
- apoptotic lymphocytes via one of the following routes: parenterally, intravenously, intramuscularly, subcutaneously, intra- dermally, and orally.
- the cell dosages described below are suitable for a 70 kg patient and may be adjusted according to body weight.
- Anti-inflammatory (and anti-thrombotic) effect, tolerance and immunosuppression induction 1.1. Administer 10 million to 1 billion cells 24 hours prior to, and 24 hours following percutaneous transluminal coronary angioplasty (PTCA) 3 such as with a stent or any other intravessel device or procedure to prevent restenosis. Administer cells 2 weeks later, as needed. 1.2. Administer 10 million to 1 billion cells during acute coronary event in order to reduce infarct size and reperfusion injury.
- PTCA percutaneous transluminal coronary angioplasty
- GVHD graft-versus-lwst disease
- Treatment of active disease Administer 10 million to 1 billion cells every 2 weeks, as needed.
- autoimmune disease Treatable autoimmune diseases include rheumatoid arthritis, idiopathic polyarthritis, multiple sclerosis, inflammatory bowel disease, scleroderma, Sjogren's syndrome, polymyositis or dermatomyositis, systemic or localized vasculitis, celiac disease, Guillain-Barre syndrome, myasthenia gravis, diabetes mellitus type I, antiphospholipid syndrome, thyroiditis. Grave's disease, and psoriasis. Can be used for treating active disease or preventing flares. Administer 10 million to 1 billion cells every 2-4 weeks, as needed.
- Treatment of chronic inflammatory or episodic inflammation- associated illnesses such as familial Mediterranean fever (FMF) and other periodic fever illnesses:
- Apoptotic neutrophils have an immunosuppressive, tolerizing, and antiinflammatory effect provided they are isolated in the right way and therapeutically administered in the right conditions and if mixed with other cells, only in controlled way (which does not occur spontaneously in leukocytes from the blood).
- Neutrophils contain proteases and other contents that may inhibit the anti-inflammatory, immunosuppressant effect if not administered correctly. Described below are methods of suitably obtaining and administering apoptotic neutrophils for treatment of various disease conditions. Materials and Methods:
- apoptotic neutrophils via one of the following routes: parenterally, intravenously, intramuscularly, subcutaneously, intra- dermally, and orally.
- the cell dosages described below are suitable for a 70 kg patient and may be adjusted according to body weight.
- Anti-inflammatory (and antithrombotic) effect, tolerance and immunosuppression induction 1.1.
- PTCA percutaneous transluminal coronary angioplasty
- Prophylactic treatment Administer 10 million to 5 billion cells 2-24 hours prior to, and 24 hours following, transplantation. Administer 10 million to 5 billion cells every 2 weeks, as needed.
- Treatment of active disease Administer 10 million to 5 billion cells every 2 weeks, as needed.
- Treatable autoimmune diseases include rheumatoid arthritis, idiopathic polyarthritis, multiple sclerosis, inflammatory bowel disease, scleroderma, Sjogren's syndrome, polymyositis or dermatomyositis, systemic or localized vasculitis, celiac disease, Guillain-Barre syndrome, myasthenia gravis, diabetes mellitus type I, antiphospholipid syndrome, thyroiditis. Grave's disease, and psoriasis. Can be used for treating active disease or preventing flares. Administer 10 million to 5 billion cells every 2-4 weeks, as needed.
- FMF familial Mediterranean fever
- Immature dedritic cells respond dramatically to LPS or other TOLL- like receptors ligands, and undergo maturation in order to initiate an immunological response. Once induced with LPS, the expression of DR ( MHC Class II) by the iDCs is upregulated along with the co-stimulation of molecules like CD86.
- adhered apoptotic monocyte cells were stained with DiI, the stained monocytes were added to iDCs at a ratio of 4:1 (monocytes to iDCs, respectively) and the treated iDCs were further subjected to LPS induction followed by FACS analyses using anti-DR-FITC and anti-CD 86-FITC antibodies.
- apoptotic cells were washed with RPMI in the absence of serum and stained with 1,1'- dioctadecyl-3,3,3'3'-teframethyl-indocarbocyanmeperchlorate (DIL) according to the manufacturer's instructions (Molecular Probes, Inc., Eugene, OR, USA).
- DIL 1,1'- dioctadecyl-3,3,3'3'-teframethyl-indocarbocyanmeperchlorate
- apoptotic monocytes For interaction of apoptotic monocytes with iDCs, 8 x 10 s apoptotic monocytes were labeled with 5 ⁇ g/ml DiI 5 as described elsewhere [Verbovetsld, 2002], and were offered to 2 x 10 5 iDCs on day six of culture (4:1 ratio) for 5 hours at 37 °C, in 96- well plates, in 300 ⁇ l of iDC culture medium. Uptake was read by a FACScanTM, as described elsewhere [Verbovetsld, 2002]. When LPS was used, it was added 1 hour following interaction with apoptotic cells and the sample was read by flow cytometry 24 hours after the LPS addition.
- iDCs were separated from monocytes based on CDIa and CD 14 staining. FSC/SSC distribution and DiI acquisition by iDCs were measured. Validation of the results was done using interaction index (Shoshan 2001). As is shown in Figures 12a-d, adhered apoptotic monocytes dramatically inhibit the effect of LPS and CD40 (not shown) whereas dying monocytes that were not adhered failed to inhibit and even increased maturation molecules on iDCs.
- Kiener PA Davis PM
- Starling GC et al. Differential induction of apoptosis by Fas-Fas ligand interactions in human monocytes and macrophages. J Exp Med 1997; 185 (8):1511-6.
- Fadok VA Bratton DL
- Konowal A Freed PW
- Westcott JY Westcott JY
- Henson PM Macrophages that have ingested apoptotic cells in-vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest 1998; 101 (4):890-8.
- Verbovetski I Bychkov H, Trahtemberg U, et al. Opsonization of apoptotic cells by autologous iC3b facilitates clearance by immature dendritic cells, down-regulates DR and CD86, and up-regulates CC chemokine receptor 7. J Exp Med 2002; 196 (12):1553-61.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Vascular Medicine (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Anesthesiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008509575A JP2008540400A (en) | 2005-05-04 | 2006-05-04 | Disease treatment using dying or dead cells |
CA002606803A CA2606803A1 (en) | 2005-05-04 | 2006-05-04 | Disease therapy using dying or dead cells |
EP06728323.4A EP1879601B1 (en) | 2005-05-04 | 2006-05-04 | Disease therapy using dying or dead cells |
IL187122A IL187122A (en) | 2005-05-04 | 2007-11-01 | Use of dying or dead cells for the preparation of medicaments for disease therapy |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/121,048 | 2005-05-04 | ||
US11/121,048 US20050202098A1 (en) | 2001-01-31 | 2005-05-04 | Disease therapy using dying or dead cells |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006117786A1 true WO2006117786A1 (en) | 2006-11-09 |
Family
ID=36781502
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IL2006/000527 WO2006117786A1 (en) | 2005-05-04 | 2006-05-04 | Disease therapy using dying or dead cells |
Country Status (5)
Country | Link |
---|---|
US (2) | US20050202098A1 (en) |
EP (2) | EP2283847A3 (en) |
JP (1) | JP2008540400A (en) |
CA (1) | CA2606803A1 (en) |
WO (1) | WO2006117786A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014087408A1 (en) | 2012-12-06 | 2014-06-12 | Enlivex Therapeutics Ltd | Therapeutic apoptotic cell preparations, method for producing same and uses thereof |
WO2014106666A1 (en) * | 2013-01-07 | 2014-07-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Disease therapy using a tolerogenic pharmaceutical preparation |
US9567568B2 (en) | 2005-05-04 | 2017-02-14 | Enlivex Therapeutics Ltd. | Method of preparing apoptotic monocytes |
US11883429B2 (en) | 2015-04-21 | 2024-01-30 | Enlivex Therapeutics Rdo Ltd | Therapeutic pooled blood apoptotic cell preparations and uses thereof |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040244806A1 (en) * | 2003-06-09 | 2004-12-09 | Ferree Bret A. | Treating disc herniation and other conditions with leukocytes |
EP2331679B1 (en) * | 2008-09-12 | 2017-04-19 | Cryopraxis Criobiologia LTDA. | Ischemic tissue cell therapy |
WO2016022972A1 (en) * | 2014-08-08 | 2016-02-11 | Alfred E. Mann Institute For Biomedical Engineering At The University Of Southern California | Apoptotic bodies |
US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
IL284985B2 (en) * | 2015-02-18 | 2023-03-01 | Enlivex Therapeutics R& D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
JP6884155B2 (en) | 2016-02-18 | 2021-06-09 | エンリヴェックス セラピューティクス リミテッド | Combination immunotherapy and cytokine control therapy for cancer treatment |
JP2022505199A (en) * | 2018-10-19 | 2022-01-14 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | Induction of transplant tolerance with a carbodiimide-treated tolerant vaccine |
CN110604743B (en) * | 2019-07-23 | 2021-08-17 | 四川大学 | Application of neutrophils in preparation of medicine for treating and/or preventing autoimmune hepatitis |
EP4197547A1 (en) * | 2021-12-20 | 2023-06-21 | Aposcience AG | Composition for treating or preventing vasculitis and diseases associated with vasculitis |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002060376A2 (en) * | 2001-01-31 | 2002-08-08 | Tolaren | Induction of tolerance by apoptotic and/or necrotic cells |
US20050202098A1 (en) * | 2001-01-31 | 2005-09-15 | Tolaren | Disease therapy using dying or dead cells |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154600B (en) * | 1971-02-10 | 1977-09-15 | Organon Nv | METHOD FOR THE DETERMINATION AND DETERMINATION OF SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES. |
NL154598B (en) * | 1970-11-10 | 1977-09-15 | Organon Nv | PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING. |
NL154599B (en) * | 1970-12-28 | 1977-09-15 | Organon Nv | PROCEDURE FOR DETERMINING AND DETERMINING SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES, AND TEST PACKAGING. |
US3901654A (en) * | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
US3853987A (en) * | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
US3867517A (en) * | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
NL171930C (en) * | 1972-05-11 | 1983-06-01 | Akzo Nv | METHOD FOR DETERMINING AND DETERMINING BITES AND TEST PACKAGING. |
US3850578A (en) * | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
US3935074A (en) * | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
US3996345A (en) * | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4034074A (en) * | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
US3984533A (en) * | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
US4098876A (en) * | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
US4879219A (en) * | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
US5011771A (en) * | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
US4666828A (en) * | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4801531A (en) * | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
US4838852A (en) * | 1987-03-27 | 1989-06-13 | Therakos, Inc. | Active specific immune suppression |
US5272057A (en) * | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
US5192659A (en) * | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
US5591457A (en) * | 1992-02-07 | 1997-01-07 | Vasogen Inc | Method of inhibiting the aggregation of blood platelets and stimulating the immune systems of a human |
US5281521A (en) * | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
AU2674097A (en) | 1996-04-17 | 1997-11-07 | Cytotherapeutics, Inc. | Method and device for delivery of apoptosis-inducing molecules |
US5951509A (en) * | 1996-11-22 | 1999-09-14 | Therakos, Inc. | Blood product irradiation device incorporating agitation |
IL133913A0 (en) * | 1997-07-10 | 2001-04-30 | Therakos Inc | Treatment of inflammatory disorders of the bowel and urinary bladder |
EP0928968A1 (en) | 1998-01-12 | 1999-07-14 | Universität Basel | Screening method for apoptosis and necrosis |
WO1999042564A2 (en) * | 1998-02-20 | 1999-08-26 | The Rockefeller University | Apoptotic cell-mediated antigen presentation to dendritic cells |
US6354297B1 (en) * | 1998-04-16 | 2002-03-12 | The Uniformed Services University Of The Health Sciences | Method and device for destroying fat cells by induction of programmed cell death |
EP1176986B1 (en) * | 1999-04-20 | 2018-07-04 | Yale University | Differentiation of monocytes into functional dendritic cells |
US7109031B2 (en) * | 1999-04-20 | 2006-09-19 | Yale University | Methods for inducing the differentiation of monocytes into functional dendritic cells and immunotherapeutic compositions including such dendritic cells |
US6219584B1 (en) * | 1999-07-09 | 2001-04-17 | Therakos, Inc. | Method and system for determining an effective amount of light energy to delivery to fluids having targets for the light energy |
-
2005
- 2005-05-04 US US11/121,048 patent/US20050202098A1/en not_active Abandoned
-
2006
- 2006-05-04 WO PCT/IL2006/000527 patent/WO2006117786A1/en not_active Application Discontinuation
- 2006-05-04 CA CA002606803A patent/CA2606803A1/en not_active Abandoned
- 2006-05-04 EP EP10183710A patent/EP2283847A3/en not_active Withdrawn
- 2006-05-04 EP EP06728323.4A patent/EP1879601B1/en active Active
- 2006-05-04 JP JP2008509575A patent/JP2008540400A/en active Pending
-
2014
- 2014-09-29 US US14/499,279 patent/US9567568B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002060376A2 (en) * | 2001-01-31 | 2002-08-08 | Tolaren | Induction of tolerance by apoptotic and/or necrotic cells |
US20050202098A1 (en) * | 2001-01-31 | 2005-09-15 | Tolaren | Disease therapy using dying or dead cells |
Non-Patent Citations (2)
Title |
---|
BEYTH ET AL: "Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness", BLOOD, vol. 105, March 2005 (2005-03-01), pages 2214 - 2219, XP002395110 * |
DE CARVALHO BITTENCOURT ET AL: "Intravenous injection of apoptotic leukocytes enhances bone marrow engraftment across major histocompatibility barriers", BLOOD, vol. 98, 2001, pages 224 - 230, XP002395074 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9567568B2 (en) | 2005-05-04 | 2017-02-14 | Enlivex Therapeutics Ltd. | Method of preparing apoptotic monocytes |
WO2014087408A1 (en) | 2012-12-06 | 2014-06-12 | Enlivex Therapeutics Ltd | Therapeutic apoptotic cell preparations, method for producing same and uses thereof |
US10077426B2 (en) | 2012-12-06 | 2018-09-18 | Enlivex Therapeutics Ltd | Therapeutic apoptotic cell preparations, method for producing same and uses thereof |
US10927343B2 (en) | 2012-12-06 | 2021-02-23 | Enlivex Therapeutics Ltd | Therapeutic apoptotic cell preparations, method for producing same and uses thereof |
WO2014106666A1 (en) * | 2013-01-07 | 2014-07-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Disease therapy using a tolerogenic pharmaceutical preparation |
US10653758B2 (en) | 2013-01-07 | 2020-05-19 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Disease therapy using a tolerogenic pharmaceutical preparation |
US11793865B2 (en) | 2013-01-07 | 2023-10-24 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Cultured phagocyte supernatent compositions |
US11883429B2 (en) | 2015-04-21 | 2024-01-30 | Enlivex Therapeutics Rdo Ltd | Therapeutic pooled blood apoptotic cell preparations and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
US9567568B2 (en) | 2017-02-14 |
JP2008540400A (en) | 2008-11-20 |
US20050202098A1 (en) | 2005-09-15 |
US20150056678A1 (en) | 2015-02-26 |
EP1879601B1 (en) | 2017-01-25 |
EP2283847A2 (en) | 2011-02-16 |
CA2606803A1 (en) | 2006-11-09 |
EP1879601A1 (en) | 2008-01-23 |
EP2283847A3 (en) | 2011-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9567568B2 (en) | Method of preparing apoptotic monocytes | |
US10927343B2 (en) | Therapeutic apoptotic cell preparations, method for producing same and uses thereof | |
AU2016250570B2 (en) | Therapeutic pooled blood apoptotic cell preparations and uses thereof | |
US11793865B2 (en) | Cultured phagocyte supernatent compositions | |
US20080305079A1 (en) | Myeloid Suppressor Cells, Methods For Preparing Them, and Methods For Using Them For Treating Autoimmunity | |
JP2013537187A (en) | Use of anti-third party central memory T cells for anti-leukemia / lymphoma treatment | |
US20180208888A1 (en) | Devices and methods for selecting apoptosis-signaling resistant cells, and uses thereof | |
EP1550454B1 (en) | Extracorporeal photopheresis in combination with anti-TNF treatment | |
Bojanic et al. | Extracorporeal photopheresis as an immunomodulatory treatment modality for chronic GvHD and the importance of emerging biomarkers | |
Rubegni et al. | CD4+ CD25+ lymphocyte subsets in chronic graft versus host disease patients undergoing extracorporeal photochemotherapy | |
IL187122A (en) | Use of dying or dead cells for the preparation of medicaments for disease therapy | |
Melk et al. | P‐glycoprotein expression is not a useful predictor of acute or chronic kidney graft rejection | |
CN109803681B (en) | Immunosuppressive composition for treating immune disorder | |
JP2004510821A (en) | Use of stem cells and CD6-depleted stem cells for inducing tolerance to allografts and / or treating leukemia | |
Einsele | Immune Therapy. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2606803 Country of ref document: CA Ref document number: 187122 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008509575 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2006728323 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006728323 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 5573/CHENP/2007 Country of ref document: IN |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: RU |
|
WWP | Wipo information: published in national office |
Ref document number: 2006728323 Country of ref document: EP |